var title_f31_3_31792="Epithelioid giant cell FNA";
var content_f31_3_31792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epithelioid giant cell: Appearance on fine needle aspirate of the thyroid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate of a papillary carcinoma of the thyroid showing an epithelioid giant cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31792=[""].join("\n");
var outline_f31_3_31792=null;
var title_f31_3_31793="Patient information: Evaluating memory and thinking problems (The Basics)";
var content_f31_3_31793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/20/2370\">",
"         Patient information: Mild cognitive impairment (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Evaluating memory and thinking problems (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/evaluating-memory-and-thinking-problems-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14235299\">",
"      <span class=\"h1\">",
"       What does &ldquo;evaluating memory and thinking problems&rdquo; mean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It means checking your memory and thinking. An &ldquo;evaluation&rdquo; is another word for a check-up or test.",
"     </p>",
"     <p>",
"      Your doctor might do an evaluation if you or your family has noticed that you are having problems with your memory or thinking, or doing daily activities.",
"     </p>",
"     <p>",
"      An evaluation can show:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If you have memory or thinking problems &ndash; It is normal for adults to have slight memory problems as they get older. But some people have memory or thinking problems that are more serious.",
"       </li>",
"       <li>",
"        The types of problems you have, and how serious they are",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      An evaluation might also show what&rsquo;s causing your problems. Different conditions can cause memory and thinking problems.",
"     </p>",
"     <p>",
"      Some people have only 1 evaluation. Other people have repeat evaluations to see if their problems get worse over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14235314\">",
"      <span class=\"h1\">",
"       What does an evaluation involve?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An evaluation involves different parts. You might have all of the parts in 1 day, or it might take a few days to do all the parts. The different parts include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Talking with your doctor or nurse &ndash; Your doctor or nurse will talk with you and your family about your symptoms, behavior, and daily activities. He or she will ask about changes in your symptoms and behavior. He or she will also ask about your medical problems, medicines, and drug and alcohol use.",
"       </li>",
"       <li>",
"        A physical exam",
"       </li>",
"       <li>",
"        Tests for your memory and thinking &ndash; The doctor or nurse will ask some questions to check your memory and thinking. For example, he or she might tell you 3 words and have you remember them for a few minutes. You might also see another person for more detailed testing.",
"       </li>",
"       <li>",
"        Blood tests &ndash; These tests can check for other conditions that could be causing your symptoms.",
"       </li>",
"       <li>",
"        A CT or MRI scan of your brain &ndash; These are imaging tests that can create pictures of your brain. Not everyone needs a brain scan. Whether or not you have a brain scan depends on your symptoms and physical exam.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14235329\">",
"      <span class=\"h1\">",
"       Why is it important to have an evaluation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to have an evaluation because some memory and thinking problems can be treated. After treatment, the symptoms will often get better.",
"     </p>",
"     <p>",
"      On the other hand, some memory or thinking problems can&rsquo;t be treated. Knowing this is helpful, too. For example, if you know that your problems might affect certain daily tasks or activities, then you can get help for those tasks or activities. Plus, if you know that your condition is not likely to improve, you and your family can make plans for the future.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14235344\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=see_link\">",
"       Patient information: Mild cognitive impairment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?31/3/31793?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16836 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31793=[""].join("\n");
var outline_f31_3_31793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14235299\">",
"      What does &ldquo;evaluating memory and thinking problems&rdquo; mean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14235314\">",
"      What does an evaluation involve?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14235329\">",
"      Why is it important to have an evaluation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14235344\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=related_link\">",
"      Patient information: Mild cognitive impairment (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31794="Patient information: Ewing sarcoma (The Basics)";
var content_f31_3_31794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/63/33778\">",
"         Patient information: Bone cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ewing sarcoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ewing-sarcoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5325666\">",
"      <span class=\"h1\">",
"       What is a Ewing sarcoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Ewing sarcoma is a type of cancer that happens most often in the bone. It happens when normal cells in the bone change into abnormal cells and grow out of control. But in some cases, a Ewing sarcoma starts in tissues outside of the bone.",
"     </p>",
"     <p>",
"      This cancer happens most often in children and teens ages 10 to 20, but it can also happen in adults. A Ewing sarcoma most often affects bones in the legs, arms, or pelvis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325681\">",
"      <span class=\"h1\">",
"       What are the symptoms of a Ewing sarcoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Ewing sarcoma usually causes pain and swelling in the area of the cancer. The pain can come and go, but it usually gets worse over weeks to months. The pain is usually worse at night and with exercise. Some people might also see or feel a lump on their bone.",
"     </p>",
"     <p>",
"      People can have other symptoms, too, depending on where the Ewing sarcoma is. For example, if the Ewing sarcoma is close to a joint, it can cause trouble with moving that joint.",
"     </p>",
"     <p>",
"      Some people also have a fever, weight loss, or feel more tired than usual.",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not a Ewing sarcoma. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325696\">",
"      <span class=\"h1\">",
"       Is there a test for a Ewing sarcoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will first order an X-ray of your bone.",
"     </p>",
"     <p>",
"      If the X-ray shows a Ewing sarcoma, you will have other tests. These will probably include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        An imaging test, such as an MRI or CT scan, of the area with the cancer &ndash; An imaging test creates pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A full-body bone scan or other imaging test, to check for cancer in other parts of your body",
"       </li>",
"       <li>",
"        A bone marrow biopsy &ndash; The bone marrow is the tissue in the middle of certain bones. During this procedure, a doctor takes a very small sample of the bone marrow. Then another doctor looks at the sample under a microscope.",
"       </li>",
"       <li>",
"        A biopsy of the Ewing sarcoma &ndash; This is a procedure in which a doctor removes a sample of the cancer. Then another doctor looks at the sample under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325711\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began, and, if so, how far.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your Ewing sarcoma and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325726\">",
"      <span class=\"h1\">",
"       How is a Ewing sarcoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Ewing sarcoma is usually treated with both:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; The type of surgery you have depends on where your cancer is and how big it is. For cancer in an arm or leg, doctors usually do &ldquo;limb-sparing&rdquo; surgery. This is when the doctor removes the cancer without removing the arm or leg. Depending on the type of surgery, the doctor might need to &ldquo;rebuild&rdquo; part of the bone after surgery.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. People with a Ewing sarcoma usually have chemotherapy both before and after their surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with a Ewing sarcoma are also treated with radiation therapy. This involves getting high doses of X-rays (radiation) aimed at your cancer. Radiation kills cancer cells. People might have radiation therapy after surgery, especially if their doctor can&rsquo;t remove all of their cancer during surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325741\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Follow-up tests can include exams, blood tests, chest X-rays, and imaging tests.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean your cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325756\">",
"      <span class=\"h1\">",
"       What happens if my Ewing sarcoma comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your Ewing sarcoma comes back or spreads, you might have more surgery, radiation, or chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325771\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for a Ewing sarcoma involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325786\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=see_link\">",
"       Patient information: Bone cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?31/3/31794?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83151 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-222.177.238.124-02425BBBD4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31794=[""].join("\n");
var outline_f31_3_31794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325666\">",
"      What is a Ewing sarcoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325681\">",
"      What are the symptoms of a Ewing sarcoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325696\">",
"      Is there a test for a Ewing sarcoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325711\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325726\">",
"      How is a Ewing sarcoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325741\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325756\">",
"      What happens if my Ewing sarcoma comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325771\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325786\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31795="Cyclopentolate: Pediatric drug information";
var content_f31_3_31795=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclopentolate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/34/24100?source=see_link\">",
"    see \"Cyclopentolate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/35/17972?source=see_link\">",
"    see \"Cyclopentolate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Pentolate&trade;;",
"     </li>",
"     <li>",
"      Cyclogyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AK Pentolate Oph Soln;",
"     </li>",
"     <li>",
"      Cyclogyl&reg;;",
"     </li>",
"     <li>",
"      Diopentolate&reg;;",
"     </li>",
"     <li>",
"      Minims Cyclopentolate;",
"     </li>",
"     <li>",
"      PMS-Cyclopentolate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Mydriatic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: See  Cyclopentolate and Phenylephrine monograph (preferred agent for use in neonates and infants due to lower cyclopentolate concentration and reduced risk for systemic reactions)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/34/24100?source=see_link\">",
"      see \"Cyclopentolate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants: See Cyclopentolate and Phenylephrine monograph (preferred agent for use in neonates and infants due to lower cyclopentolate concentration and reduced risk for systemic reactions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 1 drop of 0.5% or 1% in eye followed by 1 drop of 0.5% or 1% in 5 minutes, if necessary, approximately 40-50 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 1 drop of 1% followed by another drop in 5 minutes; approximately 40-50 minutes prior to the procedure, may use 2% solution in heavily pigmented iris",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 1% (2 mL, 15 mL); 2% (2 mL, 5 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Pentolate&trade;: 1% (2 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclogyl&reg;: 0.5% (15 mL); 1% (2 mL, 5 mL, 15 mL); 2% (2 mL, 5 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Instill drops into conjunctival sac of affected eye(s); avoid contact of bottle tip with skin or eye; to avoid excessive systemic absorption, finger pressure should be applied on the lacrimal sac during and for 1-2 minutes following application",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic procedures requiring mydriasis and cycloplegia",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, hallucinations, hyperactivity, incoherent speech, psychosis, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning sensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased, loss of visual accommodation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclopentolate or any component; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13734141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with Down syndrome (predisposition to angle-closure glaucoma); cyclopentolate may cause transient increases in intraocular pressure. Contains benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients, especially with the 2% solution; increased susceptibility to these effects has been reported in young infants, young children, and in children with spastic paralysis or brain damage; effects usually occur ~30-45 minutes after instillation. Observe neonates and infants closely for at least 30 minutes following instillation. Feeding intolerance may occur in infants; withhold feeding for 4 hours after examination. May cause transient elevation of intraocular pressure",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13763243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents the muscle of the ciliary body and the sphincter muscle of the iris from responding to cholinergic stimulation, causing mydriasis and cycloplegia",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cycloplegia: 15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mydriasis: Within 15-60 minutes, with recovery taking up to 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/35/17972?source=see_link\">",
"      see \"Cyclopentolate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause blurred vision and increased sensitivity to light",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pilocarpine ophthalmic drops applied after the examination may reduce recovery time to 3-6 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13189 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5CB361C86E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31795=[""].join("\n");
var outline_f31_3_31795=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155338\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155339\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057527\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442274\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057523\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155326\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155312\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057530\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057529\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155375\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057533\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13734141\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057522\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299107\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155321\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155323\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763243\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057521\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057532\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057526\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057534\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13189|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/34/24100?source=related_link\">",
"      Cyclopentolate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/35/17972?source=related_link\">",
"      Cyclopentolate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31796="Tigecycline: Pediatric drug information";
var content_f31_3_31796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tigecycline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"    see \"Tigecycline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/6/4196?source=see_link\">",
"    see \"Tigecycline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F786537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tygacil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9749224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tygacil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F6854571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Glycylcycline",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1038919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"      see \"Tigecycline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Safety and efficacy in children &lt;18 years of age has not been established; use in patients &lt;8 years is not recommended due to effects on tooth development; use only in highly selective cases. (Limited experience, Wyeth Pharmaceuticals; data on file; CSR-53874): Initial: 1.5 mg/kg as a single dose (maximum: 100 mg/dose). Maintenance dose: 1 mg/kg/dose (maximum: 50 mg/dose) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 100 mg as a single dose. Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Complicated skin and skin structure infection or intra-abdominal infection: 50 mg every 12 hours for 5-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Community-acquired pneumonia: 50 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Duration dependant on severity/site of infection and clinical status and response to therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     (Child-Pugh class C): Initial dose of 100 mg should be followed with a maintenance dose of 25 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F786583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tygacil&reg;: 50 mg [contains lactose 100 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F786539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1038924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Infuse over 30-60 minutes at a maximum concentration of 1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1038909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Compatible",
"     </b>",
"     with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W; final concentration should not exceed 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Dobutamine, dopamine, LR, lidocaine, potassium chloride, ranitidine, theophylline.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, chlorpromazine, methylprednisolone, voriconazole",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1038905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store vial at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Reconstituted solution may be stored at room temperature for up to 6 hours or up to 24 hours if further diluted in a compatible I.V. solution. Alternatively, may be stored refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 48 hours following immediate transfer of the reconstituted solution into NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W.  Reconstituted solution is red-orange.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1038887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Treatment of complicated skin and skin structure infections caused by susceptible organisms, including",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      S. agalactiae",
"     </i>",
"     ,",
"     <i>",
"      S. anginosus",
"     </i>",
"     group,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ,",
"     <i>",
"      B. fragilis",
"     </i>",
"     , methicillin-resistant",
"     <i>",
"      S. aureus",
"     </i>",
"     , vancomycin-susceptible",
"     <i>",
"      E. faecalis",
"     </i>",
"     ,",
"     <i>",
"      E. cloacae",
"     </i>",
"     ,",
"     <i>",
"      K. pneumoniae",
"     </i>",
"     , and rapidly-growing mycobacteria; treatment of complicated intra-abdominal infections (eg, appendicitis, cholecystitis, peritonitis, liver abscess) caused by susceptible organisms; treatment of community-acquired pneumonia caused by susceptible organisms, including",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (penicillin-susceptible isolates),",
"     <i>",
"      H. influenzae",
"     </i>",
"     (beta-lactamase negative isolates), and",
"     <i>",
"      L. pneumophila",
"     </i>",
"     (FDA approved in ages &gt;18 years and  adults).",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for the treatment of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP). Subgroup of patients with ventilator-associated pneumonia who received tigecycline demonstrated inferior efficacy, including lower cure rates and increased mortality than the comparator group.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F6154223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoproteinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, amylase increased, AST increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Abnormal healing, abscess, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal stools, anaphylaxis/anaphylactoid reactions, anorexia, aPTT prolonged, chills, creatinine increased, eosinophilia, hepatic cholestasis, hypocalcemia, hypoglycemia, hyponatremia, injection site edema, injection site inflammation, injection site pain, injection site phlebitis, injection site reaction, jaundice, leukorrhea, pancreatitis (acute), pruritus, PT prolonged, septic shock, taste perversion, thrombocytopenia, thrombophlebitis, vaginal moniliasis, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1038892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to tigecycline or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6850584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; cases of significant hepatic dysfunction and hepatic failure have been reported with tigecycline use; monitor patients for abnormal liver function tests; may need to modify dose with severe hepatic impairment. Due to structural similarity with tetracyclines, use caution in patients with prior hypersensitivity and/or severe adverse reactions associated with tetracycline use. Use caution in patients with intestinal perforation (septic shock occurred more frequently than in patients treated with imipenem/cilastatin).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1038893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      In Phase 3 and 4 clinical trials, an increase in all-cause mortality was observed in adult patients treated with tigecycline (4%) compared to those treated with comparator antibiotics (3%); cause has not been established. In general, deaths were the result of worsening infection, complications of infection, or underlying comorbidity.",
"     </b>",
"     Not indicated for the treatment of hospital-acquired pneumonia (HAP), including healthcare-associated pneumonia (HCAP) and ventilator-associated pneumonia (VAP). Demonstrated inferior efficacy (versus a comparator antibiotic), including lower cure rates and increased mortality in the subgroup of patients with VAP (particularly those with VAP and concurrent bacteremia at baseline). Life-threatening anaphylaxis/anaphylactoid reactions have been reported; use caution in patients with known tetracycline hypersensitivity. May cause fetal harm if used during pregnancy; patients should be advised of potential risks associated with use. Due to structural similarity with tetracyclines, permanent discoloration of teeth (brown-yellow-gray) may occur if used during tooth development (fetal stage through children up to 8 years of age); use may be associated with photosensitivity, pseudotumor cerebri, pancreatitis (including fatalities), and antianabolic effects (including increased BUN, azotemia, acidosis, and hyperphosphatemia). Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea or pseudomembranous colitis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F786559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Tigecycline may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F786545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F786546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects were observed in animals and because of the potential for permanent tooth discoloration, tigecycline is classified pregnancy category D. Tigecycline frequently causes nausea and vomiting and, therefore, may not be ideal for use in a patient with pregnancy-related nausea.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6850623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic hepatic function tests; resolution of infection; observe patient for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1038910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Inhibits protein synthesis by binding to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein translation and blocking entry of amino-acyl tRNA into the A site of the ribosome. Generally considered bacteriostatic; however, bactericidal activity has been demonstrated against isolates of",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     and",
"     <i>",
"      L. pneumophila",
"     </i>",
"     . Tigecycline is a derivative of minocycline (9-t-butylglycylamido minocycline), and while not classified as a tetracycline, it may share some class-associated adverse effect. Tigecycline has demonstrated activity against a variety of gram-positive and gram-negative bacterial pathogens including methicillin-resistant staphylococci.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1038912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Distribution: Extensive tissue distribution; distributes into gallbladder, lung, and colon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 7-9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Protein binding: 71% to 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Metabolism: Hepatic, via glucuronidation, N-acetylation, and epimerization to several metabolites, each &lt;10% of the dose. Clearance is reduced by 55% and half-life increased by 43% in moderate hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Half-life elimination: Single dose: 27 hours; Multiple doses: 42 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Elimination: 22% excreted in urine as unchanged drug; 59% in feces, primarily as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dialysis: Not dialysable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F6850624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/6/4196?source=see_link\">",
"      see \"Tigecycline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor teeth if &lt;8 years of age; may cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight, sunlamps, and tanning booths; wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen. May cause lightheadedness/dizziness and impair ability to perform activities requiring mental alertness or physical coordination. Women of childbearing potential should be advised to avoid becoming pregnant.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Pankey GA and Steele RW, \"Tigecycline: A Single Antibiotic for Polymicrobial Infections,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2007, 26(1):77-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31796/abstract-text/17195711/pubmed\" id=\"17195711\" target=\"_blank\">",
"        17195711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhanel GG, Homenuik K, Nichol K, et al, \"The Glycylcyclines: A Comparative Review With the Tetracyclines,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(1):63-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31796/abstract-text/14723559/pubmed\" id=\"14723559\" target=\"_blank\">",
"        14723559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13076 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31796=[""].join("\n");
var outline_f31_3_31796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786537\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9749224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6854571\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038919\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786583\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786539\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038924\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038909\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038905\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038887\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6154223\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038892\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850584\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038893\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300141\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786559\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786545\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786546\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850623\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038910\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1038912\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6850624\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13076|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=related_link\">",
"      Tigecycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/6/4196?source=related_link\">",
"      Tigecycline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31797="Tinea capitis PI";
var content_f31_3_31797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gray patch tinea capitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scales and hairs broken off one or two millimiters above the scalp are apparent in this patient with tinea capitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31797=[""].join("\n");
var outline_f31_3_31797=null;
var title_f31_3_31798="Sarcoid granuloma with calcium oxalate crystal";
var content_f31_3_31798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoid granuloma with calcium oxalate crystal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This calcium oxalate crystal in the cytoplasm of a multinucleated giant cell in a sarcoid granuloma is highly birefringent under polarized light.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laga AC, Allen TC, Bedrossian C, et al. Noncellular structures. In: Color Atlas and Text of Pulmonary Pathology, 2nd Edition, Cagle PT, Allen TC, Barrios R, et al (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31798=[""].join("\n");
var outline_f31_3_31798=null;
var title_f31_3_31799="Liposomal amphotericin B: Pediatric drug information";
var content_f31_3_31799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal amphotericin B: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"    see \"Liposomal amphotericin B: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/57/5013?source=see_link\">",
"    see \"Liposomal amphotericin B: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AmBisome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AmBisome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12857681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      <i>",
"       Candidiasis,",
"      </i>",
"     </b>",
"     <b>",
"      invasive:",
"     </b>",
"     Limited data available: I.V.: 3-5 mg/kg/dose once daily for &ge;3 weeks (Cetin, 2005; Juster-Reicher, 2003; Pappas, 2009; Queiroz-Telles, 2008); doses as high as 7 mg/kg/dose once daily have been used (Juster-Reicher, 2003); another report describes a dose escalation approach with dosing initiated with 1 mg/kg/dose on day 1 and increased by 1 mg/kg/dose once daily to a maximum of 5 mg/kg/dose once daily (preterm neonate: n=40; term neonate: n=4) (Scarcella, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"      see \"Liposomal amphotericin B: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children:",
"     <b>",
"      Note:",
"     </b>",
"     Premedication: For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: NSAID (with or without diphenhydramine)",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Empiric therapy: I.V.: 3 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment, susceptible systemic infection: I.V.: 3-5 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Aspergillosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive: I.V.: 3-5 mg/kg/dose once daily (Walsh, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive: I.V.: 5 mg/kg/dose once daily for at least 12 weeks; durations should be individualized based on clinical response (CDC, 2009); doses as high as 10 mg/kg/dose have been used in patients with documented",
"     <i>",
"      Aspergillus",
"     </i>",
"     infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Blastomycosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"     I.V.: 3-5 mg/kg/day for initial therapy, if CNS infection 4-6 weeks may be needed;  followed by oral itraconazole for a total of 12 months (Chapman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Candidiasis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive: I.V.: 3-5 mg/kg/dose once daily; duration of therapy dependent upon severity and site of infection (Filioti, 2007; Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive: I.V.: 5 mg/kg/dose once daily until 2-3 weeks after the last positive blood culture; may be used in combination with oral flucytosine for severe disease (eg, CNS involvement) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Coccidioidomycosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Disseminated infection, nonpulmonary:",
"     </i>",
"     I.V.: 2-5 mg/kg/day with or without concomitant azole antifungal (Galgiani, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Pulmonary infection, diffuse:",
"     </i>",
"     I.V.: 2-5 mg/kg/day for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months (Galgiani, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive:",
"     <i>",
"      Non-CNS infection:",
"     </i>",
"     I.V.: 3-5 mg/kg/dose once daily until clinical improvement (minimum of several weeks of therapy) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Cryptococcosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Disseminated cryptococcosis (non-CNS or severe pulmonary disease) (independent of HIV status): I.V.: 3-5 mg/kg/dose once daily; may consider addition of oral flucytosine (CDC, 2009; Perfect, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Meningitis (HIV-exposed/-positive): I.V.: 4-6 mg/kg/dose once daily with or without oral flucytosine for a minimum 2-week induction; combination with flucytosine is the preferred treatment. If renal insufficiency or infusion-related toxicity, consider lower dose: 4 mg/kg/dose once daily (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Histoplasmosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive:",
"     <i>",
"      Acute pulmonary disease:",
"     </i>",
"     I.V.: 3-5 mg/kg/day for 1-2 weeks followed by oral itraconazole for a total of 12 weeks; conventional amphotericin B typically preferred (Wheat, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Disseminated infection (non-CNS disease):",
"     </i>",
"     Acute therapy: I.V.: 3 mg/kg/dose once daily for at least 1-2 weeks for induction (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      CNS disease:",
"     </i>",
"     Acute therapy: I.V.: 5 mg/kg/dose once daily for 4-6 weeks, followed by consolidation therapy (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Visceral leishmaniasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immunocompetent patients: I.V.: Initial: 3 mg/kg/dose once daily on days 1-5; then repeat dose (3 mg/kg) on days 14 and 21.",
"     <b>",
"      Note:",
"     </b>",
"     Repeat course may be given to patients who do not achieve parasitic clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immunocompromised patients: I.V.: Initial: 4 mg/kg/dose once daily on days 1-5; then repeat dose (4 mg/kg) on days 10, 17, 24, 31, 38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Premedication: For patients who experience nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: NSAID (with or without diphenhydramine)",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     I.V.: 3-6 mg/kg/dose once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses (15 mg/kg/day) have been used clinically (Walsh, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Aspergillosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive: I.V.: 3-5 mg/kg/dose once daily (Walsh, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive: I.V.: 5 mg/kg/dose once daily for at least 12 weeks; durations should be individualized based on clinical response (CDC, 2009a); doses as high as 10 mg/kg/dose have been used in patients with documented",
"     <i>",
"      Aspergillus",
"     </i>",
"     infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Blastomycosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"     I.V.: 3-5 mg/kg/day for initial therapy, if CNS infection 4-6 weeks may be needed; followed by oral itraconazole for a total of 12 months (Chapman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Candidiasis",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Empiric therapy: 3-5 mg/kg/dose once daily (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Non-HIV-exposed/-positive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     <i>",
"      General invasive Candidal disease:",
"     </i>",
"     I.V.: 3-5 mg/kg/dose once daily  (Filioti, 2007; Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     <i>",
"      Endocarditis:",
"     </i>",
"     I.V.: 3-5 mg/kg/dose once daily (with or without flucytosine) for 6 weeks after valve replacement (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     HIV-exposed/-positive:",
"     <i>",
"      General invasive Candidal disease:",
"     </i>",
"     I.V.: 5 mg/kg/dose once daily until 2-3 weeks after the last positive blood culture; may be used in combination with oral flucytosine for severe disease (eg, CNS involvement) (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Coccidioidomycosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Disseminated infection, nonpulmonary:",
"     </i>",
"     I.V.: 2-5 mg/kg/day with or without concomitant azole antifungal (Galgiani, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Pulmonary infection, diffuse:",
"     </i>",
"     I.V.: 2-5 mg/kg/day for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months (Galgiani, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive:",
"     <i>",
"      Non-CNS infection:",
"     </i>",
"     I.V.: 4-6 mg/kg/dose once daily until clinical improvement (minimum of several weeks of therapy) (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Cryptococcosis",
"      </i>",
"     </b>",
"     <b>",
"      , invasive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Disseminated cryptococcosis (non-CNS or severe pulmonary disease) (independent of HIV status): I.V.: 3-5 mg/kg/dose once daily; may consider addition of oral flucytosine (CDC, 2009a; Perfect, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Meningitis (HIV-exposed/-positive): I.V.: 4-6 mg/kg/dose once daily in combination with oral flucytosine (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Histoplasmosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive: I.V.: 3-5 mg/kg/day for 1-2 weeks followed with itraconazole (Wheat, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Non-CNS infection:",
"     </i>",
"     3 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      CNS infection:",
"     </i>",
"     5 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Sporotrichosis",
"      </i>",
"     </b>",
"     <b>",
"      infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Disseminated, pulmonary, or osteoarticular disease: 3-5 mg/kg/day, followed by oral itraconazole after a favorable response is seen with amphotericin initial therapy (Kauffman, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Meningeal: I.V.: 5 mg/kg/day for 4-6 weeks, followed by oral itraconazole (Kauffman, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Visceral leishmaniasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immunocompetent: I.V.: 3 mg/kg/dose on days 1-5, and 3 mg/kg/dose on days 14 and 21; a repeat course may be given in patients who do not achieve parasitic clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive: I.V.: 2-4 mg/kg/dose once daily for 10 days or an interrupted schedule of 4 mg/kg/dose on days 1-5, and on days 10, 17, 24, 31, and 38 (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Premedication: For patients who experience nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: NSAID (with or without diphenhydramine)",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"     I.V.: 3-6 mg/kg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses (15 mg/kg/day) have been used clinically (Walsh, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AmBisome&reg;: 50 mg [contains soy, sucrose 900 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Reconstitute with 12 mL SWI to a concentration of 4 mg/mL; shake vigorously for at least 30 seconds, until dispersed into a translucent yellow suspension; a 5-micron filter should be on the syringe used to inject the reconstituted product from the vial into the diluent. AmBisome&reg; may be diluted with D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, or D",
"     <sub>",
"      25",
"     </sub>",
"     W to a final concentration of 1-2 mg/mL; in infants and small children, a lower concentration of 0.2-0.5 mg/mL may be used to provide sufficient volume for infusion. Do not use in-line filter less than 1 micron to administer AmBisome&reg;. Flush line with D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to infusion; infusion of diluted AmBisome&reg; should start within 6 hours of preparation; infuse over 2 hours; infusion time may be reduced to 1 hour in patients who tolerate the treatment",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, other saline-containing solutions, or preservatives.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caspofungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doripenem.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened vials at temperatures &le;25&deg;C (&le;77&deg;F); reconstituted drug is stable for 24 hours under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not dilute with saline solutions or mix with other drugs or electrolytes; may cause precipitant formation. Manufacturer&rsquo;s labeling states infusion should begin within 6 hours of dilution with D",
"     <sub>",
"      5",
"     </sub>",
"     W; data on file with Astellas Pharma shows extended formulation stability (see table) when admixed at 0.2-2 mg/mL (in polyolefin or polyvinyl chloride bags) in various dextrose solutions. For infants and small children, dilutions of 0.2-0.5 mg/mL may be used.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      AmBisome&reg; Stability",
"     </caption>",
"     <col align=\"left\" width=\"75\">",
"     </col>",
"     <col align=\"left\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Solution",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Temperature",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Stability",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"         <sub>",
"          5",
"         </sub>",
"         W",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         2 mg/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2&deg;C to 8&deg;C",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         0.2 mg/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2&deg;C to 8&deg;C",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         0.2-2 mg/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         23&deg;C to 27&deg;C",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"         <sub>",
"          10",
"         </sub>",
"         W",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         0.2-2 mg/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2&deg;C to 8&deg;C",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"         <sub>",
"          20",
"         </sub>",
"         W",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         2 mg/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2&deg;C to 8&deg;C",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"         <sub>",
"          25",
"         </sub>",
"         W",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         2 mg/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2&deg;C to 8&deg;C",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48 hours",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Empirical therapy for presumed fungal infection in febrile, neutropenic patients; treatment of patients with",
"     <i>",
"      Aspergillus",
"     </i>",
"     species,",
"     <i>",
"      Candida",
"     </i>",
"     species, and/or",
"     <i>",
"      Cryptococcus",
"     </i>",
"     species infections refractory to amphotericin B desoxycholate (conventional amphotericin), or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B desoxycholate; treatment of cryptococcal meningitis in HIV-infected patients; treatment of visceral leishmaniasis (all indications: FDA approved in ages &ge;1 month and adults). Has also been used for treatment of systemic",
"     <i>",
"      Histoplasmosis",
"     </i>",
"     infection, blastomycosis, coccidioidomycosis, and mucormycosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lipid-based amphotericin formulations (AmBisome&reg;) may be confused with conventional formulations (Amphocin&reg;, Fungizone&reg;) or with other lipid-based amphotericin formulations (Abelcet&reg;, Amphotec&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F134907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nephrotoxicity and infusion-related hyperpyrexia, rigor, and chilling are reduced relative to amphotericin deoxycholate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, chest pain, edema, facial swelling, hyper-/hypotension, hypervolemia, orthostatic hypotension, peripheral edema, tachycardia, vascular heart disease, vascular disorder, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, agitation, anxiety, chills, coma, confusion, depression, dizziness, dysesthesia, hallucinations, headache, insomnia, malaise, nervousness, pain, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, cellulitis, dry skin, maculopapular rash, petechia, pruritus, purpura, rash, skin discoloration, skin disorder, skin ulcer, urticaria, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, fluid overload, hyperchloremia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hyperphosphatemia, hyperproteinemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, lactate dehydrogenase increased, nonprotein nitrogen increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abdomen enlarged, amylase increased, anorexia, constipation, diarrhea, dry mouth, dyspepsia, dysphagia, eructation, fecal incontinence, flatulence, gastrointestinal hemorrhage, gum/oral hemorrhage, hematemesis, hemorrhoids, ileus, mucositis, nausea, rectal disorder, stomatitis, ulcerative stomatitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, blood transfusion reaction, coagulation disorder, hemorrhage, leukopenia, prothrombin increased, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubinemia, hepatocellular damage,  hepatomegaly, liver function tests abnormal (not specified), veno-occlusive liver disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site inflammation, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, bone pain, dystonia, myalgia, neck pain, paresthesia, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, dry eyes, eye hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, BUN increased, creatinine increased, dysuria, hematuria, renal failure, renal function abnormal, toxic nephropathy, nephrotoxicity, urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, atelectasis, cough, dry nose, dyspnea, epistaxis, hemoptysis, hyperventilation, hypoxia, lung disorder, pharyngitis, pleural effusion, pneumonia, pulmonary edema, respiratory alkalosis, respiratory failure, respiratory insufficiency,  rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, cell-mediated immunological reaction, diaphoresis, flu-like syndrome, graft-versus-host disease, herpes simplex, hiccup, infection, infusion reaction, procedural complication, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, angioedema, bronchospasm, cyanosis/hypoventilation, erythema, hemorrhagic cystitis, rhabdomyolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amphotericin B desoxycholate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the nephrotoxic potential of amphotericin B, other nephrotoxic drugs should be avoided. Acute infusion reactions (including fever and chills) may occur 1-2 hours after starting infusions; reactions are more common with the first few doses and generally diminish with subsequent doses administered at a slower infusion rate. Acute pulmonary reactions have been reported in patients simultaneously receiving intravenous amphotericin B and leukocyte transfusions; separate these infusions temporally as much as possible and monitor pulmonary function. Concurrent use with antineoplastic agents may enhance the potential for renal toxicity, bronchospasm, or hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anaphylaxis has been reported with amphotericin B-containing drugs; if a severe anaphylactic reaction occurs, discontinue infusion immediately; patient should not receive further infusions of amphotericin B liposome; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Amphotericin B may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6866584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (King, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN, serum creatinine, liver function tests, serum electrolytes (particularly magnesium and potassium), CBC, vital signs, I &amp; O; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes); monitor cardiac function if used concurrently with corticosteroids",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exhibits nonlinear kinetics (greater than proportional increase in serum concentration with an increase in dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.1-0.16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (terminal): 100-153 hours",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F15589751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The lipid portion of amphotericin B (liposomal) formulation contains 0.27 kcal per 5 mg; for patients receiving parenteral nutrition, adjustment to the amount of lipids may be necessary (Sacks, 1997).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cetin H, Yalaz M, Akisu M, et al, \"The Efficacy of Two Different Lipid-Based Amphotericin B in Neonatal Candida Septicemia,\"",
"      <i>",
"       Pediatr Int",
"      </i>",
"      , 2005, 47(6):676-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/16354223/pubmed\" id=\"16354223\" target=\"_blank\">",
"        16354223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman SW, Dismukes WE, Proia LA, et al, \"Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(12):1801-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/18462107/pubmed\" id=\"18462107\" target=\"_blank\">",
"        18462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emminger W, Graninger W, Emminger-Schmidmeir W, et al, &ldquo;Tolerance of High Doses of Amphotericin B by Infusion of a Liposomal Formulation in Children With Cancer,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 1994, 68:27-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/8110875/pubmed\" id=\"8110875\" target=\"_blank\">",
"        8110875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filioti J, Spiroglou K, Panteliadis CP, et al, \"Invasive Candidiasis in Pediatric Intensive Care Patients: Epidemiology, Risk Factors, Management, and Outcome,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2007, 33(7):1272-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/17503015/pubmed\" id=\"17503015\" target=\"_blank\">",
"        17503015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galgiani JN, Ampel NM, Blair JE, et al, \"Coccidioidomycosis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1217-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/16206093/pubmed\" id=\"16206093\" target=\"_blank\">",
"        16206093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juster-Reicher A, Flidel-Rimon O, Amitay M, \"High-Dose Liposomal Amphotericin B in the Therapy of Systemic Candidiasis in Neonates,\"",
"      <i>",
"       Eur J Clin Microbiol Infect Dis",
"      </i>",
"      , 2003, 22(10):603-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Bustamante B, Chapman SW, et al, \"Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(10):1255-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/17968818/pubmed\" id=\"17968818\" target=\"_blank\">",
"        17968818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of",
"      <i>",
"       Candidiasis",
"      </i>",
"      : 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, \"Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Queiroz-Telles F, Berezin E, Leverger G, et al, \"Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2008, 27(9):820-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/18679151/pubmed\" id=\"18679151\" target=\"_blank\">",
"        18679151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacks GS and Cleary JD, \"Nutritional Impact of Lipid-Associated Amphotericin B Formulations,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(1):121-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/8997484/pubmed\" id=\"8997484\" target=\"_blank\">",
"        8997484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scarcella A, Pasquariello MB, Giugliano B, et al, \"Liposomal Amphotericin B Treatment for Neonatal Fungal Infections,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(2):146-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/9493812/pubmed\" id=\"9493812\" target=\"_blank\">",
"        9493812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Glaser CA, Bloch KC, et al, \"The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 47(3):303-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/18582201/pubmed\" id=\"18582201\" target=\"_blank\">",
"        18582201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al, \"Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(3):327-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/18177225/pubmed\" id=\"18177225\" target=\"_blank\">",
"        18177225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Finberg RW, Arndt C, et al, &ldquo;Liposomal Amphotericin B for Empirical Therapy in Patients With Persistent Fever and Neutropenia,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      1999, 340:764-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/10072411/pubmed\" id=\"10072411\" target=\"_blank\">",
"        10072411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Goodman JL, Pappas P, et al, &ldquo;Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome&reg;) in Patients Infected With Aspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(12):3487-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/11709329/pubmed\" id=\"11709329\" target=\"_blank\">",
"        11709329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al, \"Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of  America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(7):807-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/3/31799/abstract-text/17806045/pubmed\" id=\"17806045\" target=\"_blank\">",
"        17806045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12669 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B3B70EFBF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31799=[""].join("\n");
var outline_f31_3_31799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134882\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045142\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12857681\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045135\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134867\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134852\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045145\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134908\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045138\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045144\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134910\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134907\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045148\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045134\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045133\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298746\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134863\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866584\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045141\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045132\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045147\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589751\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12669\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12669|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=related_link\">",
"      Liposomal amphotericin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/57/5013?source=related_link\">",
"      Liposomal amphotericin B: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31800="Male reproductive physiology";
var content_f31_3_31800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Male reproductive physiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31800/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31800/contributors\">",
"     James E Griffin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31800/contributors\">",
"     Jean D Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31800/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31800/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31800/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31800/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/3/31800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the normal hypothalamic-pituitary-testicular axis, androgen physiology, sperm formation, and sexual maturation at puberty and its subsequent maintenance. The roles of testosterone, which directly stimulates Wolffian duct differentiation, and dihydrotestosterone, which causes development of the external genitalia in male sexual differentiation, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"     \"Normal sexual differentiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE OF THE TESTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The testes contain two anatomical units:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A network of tubules in which inhibin and anti-m&uuml;llerian hormone are synthesized and sperm are produced.",
"     </li>",
"     <li>",
"      An interstitium containing Leydig cells that produce androgens and myoid cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The spermatogenic tubules are composed of germ cells and Sertoli cells. Tight junctions between the Sertoli cells separate the tissue into two functional compartments (basal and adluminal), which are distinct from the anatomical units and which have limited permeability for diffusion of macromolecules between them (",
"    <a class=\"graphic graphic_figure graphicRef69256 \" href=\"UTD.htm?5/19/5430\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/1\">",
"     1",
"    </a>",
"    ]. The",
"    <strong>",
"     basal",
"    </strong>",
"    compartment consists of the Leydig cells, the boundary tissue of the tubules including the peritubular myoid cells, and the outer layers of the tubules containing the spermatogonia. The",
"    <strong>",
"     adluminal",
"    </strong>",
"    compartment contains the inner portion of the tubules, including primary spermatocytes and more advanced stages of spermatogenesis.",
"   </p>",
"   <p>",
"    As spermatogenesis begins, the spermatogonia pass through the tight junctions between Sertoli cells so that the Sertoli cell cytoplasm encompasses the differentiating spermatocytes and spermatids as they move toward the lumen of the tubules. The tubules empty into a network of ducts termed the rete testes, through which the sperm move to the epididymis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE HYPOTHALAMIC-PITUITARY-TESTICULAR AXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothalamus communicates with the pituitary via a portal vascular system and by neural pathways (",
"    <a class=\"graphic graphic_figure graphicRef68189 \" href=\"UTD.htm?13/43/14002\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=see_link\">",
"     \"Hypothalamic-pituitary axis\"",
"    </a>",
"    .) The preoptic area and the medial basal region of the hypothalamus (particularly the arcuate nucleus) contain neurons that secrete gonadotropin-releasing hormone (GnRH) in a pulsatile fashion, the so-called GnRH pulse generator. Several hormones, neurotransmitters, and cytokines modulate GnRH secretion (",
"    <a class=\"graphic graphic_figure graphicRef68189 \" href=\"UTD.htm?13/43/14002\">",
"     figure 2",
"    </a>",
"    ). Kisspeptin and its receptor, KISS1R (also called GPR54), are also important in GnRH secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     GnRH actions in the pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulsatile secretion of GnRH into the hypophyseal portal system in turn elicits pulsatile secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the gonadotroph cells of the anterior pituitary [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/2\">",
"     2",
"    </a>",
"    ]. The pulsatility of GnRH secretion is essential for the stimulation of LH and FSH release; continuous administration of GnRH or GnRH agonists inhibits gonadotropin release (",
"    <a class=\"graphic graphic_figure graphicRef51212 \" href=\"UTD.htm?19/58/20398\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    LH and FSH are composed of two glycoprotein chains. The alpha-subunits of the two chains are identical; distinct immunologic and functional characteristics of the two hormones are conveyed by the unique beta-subunits.",
"   </p>",
"   <p>",
"    GnRH binds to cell surface receptors on the pituitary gonadotrophs to stimulate the release of both LH and FSH by a calcium-dependent mechanism that is independent of cyclic AMP (cAMP) and that may involve diacylglycerols [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/3\">",
"     3",
"    </a>",
"    ]. The amount of LH and FSH released depends upon the age of the individual (the hormonal milieu) and upon the frequency and magnitude of the GnRH pulses.",
"   </p>",
"   <p>",
"    LH and FSH are composed of two glycoprotein subunits. The alpha-subunits are identical; distinct immunologic and functional characteristics of the two hormones are conveyed by the unique beta-subunits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gonadotropin actions in the testes",
"    </span>",
"    &nbsp;&mdash;&nbsp;LH interacts with receptors on the Leydig cell membrane to stimulate adenyl cyclase and the formation and release of cAMP. cAMP activates the catalytic subunit of a protein kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/4\">",
"     4",
"    </a>",
"    ] and through a series of incompletely understood intermediate steps enhances testosterone synthesis.",
"   </p>",
"   <p>",
"    FSH interacts with receptors on the basal aspect of the Sertoli cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/5\">",
"     5",
"    </a>",
"    ] to stimulate cAMP generation and activate protein kinase. As a result, the synthesis of several proteins is enhanced, including androgen binding protein (ABP) and the aromatase enzyme (CYP19) that converts testosterone to estradiol&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/6\">",
"     6",
"    </a>",
"    ]. The mechanism by which FSH regulates spermatogenesis is incompletely understood (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Feedback control of gonadotropin secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men, LH secretion is regulated primarily by negative feedback, as normal concentrations of gonadal steroids inhibit LH secretion. Testosterone can be converted to estradiol by CYP19 in the brain and the pituitary, but the two hormones are thought to regulate gonadotropin secretion independently. Estradiol appears to be more important than testosterone in the regulation of FSH secretion in men [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/7\">",
"     7",
"    </a>",
"    ], but aromatization of testosterone does not appear to be required for negative feedback control of LH synthesis because dihydrotestosterone, an androgen that cannot be aromatized, also inhibits LH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/8\">",
"     8",
"    </a>",
"    ]. The fact that LH levels are elevated in men with aromatase deficiency and following the administration of aromatase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/9\">",
"     9",
"    </a>",
"    ] implies that estradiol action is involved in LH feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testosterone acts on the hypothalamus to slow the hypothalamic pulse generator and decrease LH pulse frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/11\">",
"     11",
"    </a>",
"    ], probably by a mechanism involving endogenous opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/12\">",
"     12",
"    </a>",
"    ]. Testosterone also appears to inhibit LH release directly at the level of the pituitary [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/13\">",
"     13",
"    </a>",
"    ]. Some of these effects may be mediated by the local conversion of testosterone to estradiol. In adult men, estrogen inhibits LH secretion both by decreasing GnRH pulse frequency at the level of the hypothalamus and by reducing the amplitude of LH pulses by impairing pituitary responsiveness to GnRH [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Feedback control of FSH secretion involves both peptide and steroid hormones. The serum FSH concentration increases with loss of germinal elements in the testis without a concomitant increase in LH concentration. Inhibin, a peptide inhibitor of pituitary FSH secretion that is produced by germ cells beginning at puberty, is a glycoprotein consisting of two disulfide-linked subunits, alpha and beta. Because the beta subunit can exist in two forms, there are two forms of inhibin, inhibin A and inhibin B. Both FSH and androgen are required for normal inhibin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/14\">",
"     14",
"    </a>",
"    ]. Inhibin blocks GnRH-stimulated FSH release, and in the castrated rhesus monkey inhibin is capable of returning FSH levels to normal in the absence of testosterone&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/15\">",
"     15",
"    </a>",
"    ]. Inhibin B is the physiologically important hormone in men [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. An inverse relationship between inhibin B and FSH level occurs across a wide range of FSH concentrations in normal and infertile men. In adult men, the level of inhibin B correlates with the presence of germ cells in early spermatogenesis rather than with the presence of Sertoli cells as seen before puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothalamic-pituitary-testicular axis is exquisitely sensitive to stressors. Acute and chronic illnesses lower testosterone levels as a result of increased corticotropin releasing hormone and cytokine release [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Fasting reduces testosterone levels in healthy men by acutely lowering levels of leptin, which is required for normal pulse generator activity (",
"    <a class=\"graphic graphic_figure graphicRef68189 \" href=\"UTD.htm?13/43/14002\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANDROGEN SYNTHESIS, TRANSPORT, METABOLISM, AND ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synthesis and metabolism of testosterone to the active metabolites, 5-alpha-dihydrotestosterone and 17-beta-estradiol, are diagrammed in the figure (",
"    <a class=\"graphic graphic_figure graphicRef65690 \" href=\"UTD.htm?39/20/40271\">",
"     figure 4",
"    </a>",
"    ). Cholesterol, the precursor steroid, can either be synthesized in the Leydig cell or derived from the plasma pool via uptake of low density lipoproteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Androgen synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five enzymatic processes are involved in the conversion of cholesterol to testosterone:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cholesterol side chain cleavage (CYP11A1)",
"     </li>",
"     <li>",
"      3-beta-hydroxysteroid",
"      <span class=\"nowrap\">",
"       dehydrogenase/isomerase",
"      </span>",
"      (3-beta-HSD)",
"     </li>",
"     <li>",
"      17-alpha-hydroxylase (CYP17)",
"     </li>",
"     <li>",
"      17,20-lyase (CYP17)",
"     </li>",
"     <li>",
"      17-beta-hydroxysteroid dehydrogenase 3(17-beta-HSD3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conversion of cholesterol to pregnenolone is the rate-limiting reaction in steroidogenesis, but under most conditions the rate is determined not by the activity of the side-chain cleavage enzyme (CYP11A1), but rather by the rate of delivery of cholesterol to the enzyme in the inner mitochondrial membrane by the steroidogenic acute regulatory protein (StAR), a process that may be the main site of action of LH [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholesterol side chain cleavage takes place in the mitochondria, and the remaining reactions occur in the endoplasmic reticulum. A single CYP17 enzyme possesses both 17-alpha-hydroxylase and 17,20-lyase activities; the mechanisms by which the two enzymatic functions are controlled are poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/25\">",
"     25",
"    </a>",
"    ], but mutations in different parts of the gene can influence the two processes selectively [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/26\">",
"     26",
"    </a>",
"    ]. About 25 mcg of testosterone are present in the normal testes, and on average, 5 to 10 mg of testosterone are secreted daily in a pulsatile fashion under the control of LH [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/27\">",
"     27",
"    </a>",
"    ]. In normal young men sleep-induced increases in testosterone cause testosterone levels to peak in the early morning [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/28\">",
"     28",
"    </a>",
"    ]. Additional factors that influence Leydig cell function include insulin-like growth factor-I, transforming growth factors alpha and beta, epidermal growth factor, and fibroblast growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Testosterone metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone can be converted to 5-alpha-dihydrotestosterone, which mediates many of the differentiative, growth-promoting, and functional aspects of androgen action in males (",
"    <a class=\"graphic graphic_figure graphicRef65690 \" href=\"UTD.htm?39/20/40271\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"     \"Normal sexual differentiation\"",
"    </a>",
"    .) Alternatively, testosterone can be aromatized to estrogens, which exert effects that are independent of, opposite to, or synergistic to those of androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating dihydrotestosterone is formed principally in androgen target tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/31\">",
"     31",
"    </a>",
"    ]. In normal men, dihydrotestosterone formation accounts for about 6 to 8 percent of testosterone metabolism, and the ratio of plasma testosterone to dihydrotestosterone approximates 10 to 15:1. A number of delta-4, 3-keto-steroids can be 5-alpha-reduced, a reaction that is physiologically irreversible. There are two separate 5-alpha-reductase isoenzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/32\">",
"     32",
"    </a>",
"    ]. Enzyme 1 is expressed in liver and nongenital skin. Enzyme 2 is expressed in the male urogenital tract, genital skin, and liver and is defective in subjects with 5-alpha-reductase 2 deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=see_link\">",
"     \"Steroid 5-alpha-reductase 2 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principal role of dihydrotestosterone formation appears to be amplification of the androgen signal, presumably because of the higher affinity of dihydrotestosterone for binding to the AR (most easily demonstrated as a slower dissociation rate of the dihydrotestosterone-AR complex [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/33\">",
"     33",
"    </a>",
"    ]). The strongest evidence for this concept is the fact that targeted disruption of both steroid 5-alpha-reductase enzymes in the mouse does not impair virilization because it is associated with a profound increase in testosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/34\">",
"     34",
"    </a>",
"    ]. The dihydrotestoterone-AR complex may also exert some unique role(s) in male physiology.",
"   </p>",
"   <p>",
"    Estrogens act in concert with androgens to inhibit gonadotropin secretion (see above) and to promote bone maturation in the adolescent boy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/10\">",
"     10",
"    </a>",
"    ]. Estrogen excess in men can be either relative or absolute and is usually manifested by breast enlargement (gynecomastia). Androgens act in the breast to inhibit the actions of estrogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the 50 mcg of estradiol formed daily in normal adult men, about 85 percent is synthesized in extraglandular tissues, and the remainder in the testes. The conversion of androgens to estrogens in testis and in extraglandular tissues is catalyzed by the same CYP19 present in the placenta and ovary, a microsomal enzyme whose expression is determined by tissue specific promoters [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/35\">",
"     35",
"    </a>",
"    ]. Adipose tissue is the most significant site of estrogen formation in normal men, and the overall rate of estrogen synthesis in extraglandular tissue rises with increasing body weight and advancing age. Increases in the serum LH concentration enhance the secretion of estradiol by the testes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transport of gonadal steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadal steroids are transported in the plasma largely bound to albumin and sex hormone-binding globulin (SHBG, also called testosterone-binding globulin or TeBG). In normal men, approximately 2 percent of plasma testosterone is free or unbound, 44 percent is bound to SHBG, and 54 percent is bound to albumin and other proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/36\">",
"     36",
"    </a>",
"    ]. Although it has about 1000-fold lower affinity for testosterone binding than does SHBG, albumin binds half or more of plasma testosterone because of its high concentration. Since nearly all of the albumin-bound testosterone is available for tissue uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/37\">",
"     37",
"    </a>",
"    ], bioavailable testosterone in plasma approximates the",
"    <strong>",
"     sum",
"    </strong>",
"    of free plus albumin-bound hormone.",
"   </p>",
"   <p>",
"    The concentration of SHBG in men is about one-third to one-half that in women, and prepubertal boys and hypogonadal men have higher SHBG levels than normal men. The serum SHBG concentration is decreased by androgen administration and by hypothyroidism and increased by estrogen administration and hyperthyroidism. Alterations in the SHBG concentration do not affect androgen physiology in the steady state in normal men because the hypothalamic-pituitary system responds to acute changes in concentrations of bioavailable testosterone by altering testosterone synthesis and reestablishing a normal serum level of bioavailable testosterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Androgen action",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the physiological actions of testosterone are the result of the combined effects of testosterone itself plus its active androgenic and estrogen metabolites. The major functions of androgens in males include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Regulation of gonadotropin secretion by the hypothalamic-pituitary system",
"     </li>",
"     <li>",
"      Initiation and maintenance of spermatogenesis",
"     </li>",
"     <li>",
"      Formation of the male phenotype during embryogenesis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"       \"Normal sexual differentiation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Promotion of sexual maturation at puberty and its maintenance thereafter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, testosterone increases lean body mass and decreases fat mass. The reciprocal change in lean and fat mass is thought to be a result of promotion of development of mesenchymal stem cells into muscle rather than into adipocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Classical pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inside target cells, testosterone and dihydrotestosterone bind to the same high-affinity androgen receptor protein (AR). Binding of the hormone to the receptor causes a conformational change that causes dissociation of the receptor from heat shock proteins such as hsp90. The hormone-receptor complex then forms a homodimer with a second hormone-AR receptor molecule.",
"   </p>",
"   <p>",
"    The human AR cDNA predicts that the receptor has on average 917 amino acids and a mass of about 99 kD (",
"    <a class=\"graphic graphic_figure graphicRef61536 \" href=\"UTD.htm?34/56/35724\">",
"     figure 5",
"    </a>",
"    ). The AR is a member of the steroid-thyroid-retinoid superfamily of hormone receptors that act as transcription regulatory factors and have conserved C-terminal regions for hormone- and DNA-binding. The N-terminal and hinge regions of the AR bind the co-activator and co-repressor proteins that combine with the AR-androgen complex to form the transcription regulatory complex [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The N-terminal region contains three homopolymeric repeat regions. The glutamine-repeat region averages 20 amino acids but is highly polymorphic in length; significant expansion (Kennedy syndrome or spinobulbar muscular atrophy) or shortening of the glutamine repeats impairs androgen action [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The active transcriptional regulatory complex binds with high affinity to androgen response elements (AREs) in DNA sequences. The AREs were originally thought to be located near the promoter region of genes, but it is now known that the AREs are linked by looping of the DNA to additional AREs to form complex binding sites for the transcriptional regulatory complex [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/42\">",
"     42",
"    </a>",
"    ]. The net consequence is to either upregulate or downregulate the transcription of genes under androgen control [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Non-classical pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"non-classical\" androgen action refers to mechanisms that do not utilize the \"classical\" pathway described above, ie, they do not involve binding of the AR-transcription regulatory complex to AREs in DNA with effects on transcription hours to days later. These non-classical actions are also sometimes referred to as \"non-genomic\" actions or \"rapid\" actions because they take place within seconds and may involve cell surface binding. The term \"non-genomic\" may be incorrect because some non-classical androgen action pathways involve second messengers eventually leading to genomic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The non-classical action pathway can be mediated by several mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The classical intracellular androgen receptor via activation of a co-regulator such as steroid receptor co-activator (Src) kinase not requiring gene transcription",
"     </li>",
"     <li>",
"      Direct binding to specific-binding sites of target molecules in the absence of the androgen receptor",
"     </li>",
"     <li>",
"      Distinct non-classical cell surface transmembrane androgen receptors or seven-transmembrane receptors that transmit signals via G-proteins",
"     </li>",
"     <li>",
"      Changes in membrane permeability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-classical androgen actions have been demonstrated in the reproductive, cardiovascular, immune, and musculoskeletal systems [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/44\">",
"     44",
"    </a>",
"    ]. In Sertoli cells, for example, non-classical androgen signaling pathways are responsible for the stimulation of calcium influx and activation of the mitogen-activated protein kinase (MAPK) pathway. Testosterone in physiological concentrations, even when it is conjugated to bovine serum albumin as a membrane-impermeable analogue, binds to cell surface ARs and causes increased intracellular calcium in Sertoli cells by enhancing the influx of extracellular calcium influx [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/44\">",
"     44",
"    </a>",
"    ]. The increased intracellular calcium activates various kinases. In a second pathway, classical androgen receptors in the plasma membrane can activate the MAPK pathway working through the epidermal growth factor receptor. Non-classical actions of testosterone in Sertoli cells likely work in tandem with the classical actions to promote spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPERMATOGENESIS AND ITS REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each spermatogonium that undergoes differentiation after puberty gives rise to 16 primary spermatocytes, each of which then enters meiosis and gives rise to four spermatids and finally four spermatozoa (",
"    <a class=\"graphic graphic_figure graphicRef75640 \" href=\"UTD.htm?38/40/39567\">",
"     figure 6",
"    </a>",
"    ). Thus, the 3 million spermatogonia that begin the process each day give rise to approximately 200 million spermatozoa [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/48\">",
"     48",
"    </a>",
"    ]. Since about one-half of potential sperm die during this process, 100 million sperm are produced each day [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/48\">",
"     48",
"    </a>",
"    ]. A spermatogonia-specific transcription factor, Plzf, identified in mice, is the first mammalian gene known to be required for stem cell self-renewal [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transformation of the spermatid into a mature sperm requires restructuring of the blood-testis barrier and involves reorganization of the nucleus and cytoplasm and development of a flagellum [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/51\">",
"     51",
"    </a>",
"    ]. The nucleus relocates to an eccentric position at the head of the spermatid and is covered by an acrosomal cap. The cilial core of the sperm tail consists of nine outer fibers and two inner fibers surrounded in the middle section by mitochondria and in the terminal section only by a cell membrane.",
"   </p>",
"   <p>",
"    Sperm motility is due to the sliding action of the fibers in the axial structure of the tail. The fibers (or microtubules) are attached to each other by arms that contain the protein dynein, an ATPase. Hydrolysis of ATP generated in adjacent mitochondria provides energy for motility.",
"   </p>",
"   <p>",
"    Sperm formation takes approximately 70 days from the spermatocyte stage, and the transport of sperm through the epididymis to the ejaculatory ducts requires about 14 days. Some maturation of sperm occurs during passage through the epididymis, as evidenced by enhancement of motility, but the final maturation (or capacitation) of sperm may take place after ejaculation into the female urogenital tract.",
"   </p>",
"   <p>",
"    Normal spermatogenesis requires the lower temperature of the scrotum compared to that in the abdomen. However, a slight increase in scrotal temperature of about 1&ordm;C, as for example with the wearing of athletic scrotal supports, does not appear to impair sperm number or quality [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hormonal control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main hormones that control spermatogenesis are FSH and testosterone. FSH receptors are present in Sertoli cells and spermatogonia, and AR is present in Sertoli cells, Leydig cells, and peritubular myoid cells. FSH acts directly on the Sertoli cell to increase production of androgen-binding protein, transferrin, inhibin, CYP19, and plasminogen activators [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/53\">",
"     53",
"    </a>",
"    ]. FSH also enhances glucose transport and the conversion of glucose to lactate in Sertoli cells.",
"   </p>",
"   <p>",
"    The production of testosterone in Leydig cells under the control of LH results in an intratesticular testosterone concentration approximately 100 times greater than that in the peripheral circulation. Sertoli cells contain AR, and a Sertoli cell-selective knockout of AR in mice causes spermatogenic arrests in meiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both LH and FSH play roles in normal spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/55\">",
"     55",
"    </a>",
"    ]. For example, spermatogenesis does not occur spontaneously in men with hypogonadotropic hypogonadism of prepubertal onset. Spermatogenesis can be initiated in these men by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG), which has potent LH effects, and an FSH preparation, such as human menopausal gonadotropin (hMG) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In men who develop hypogonadotropic hypogonadism in adulthood, eg, because of a pituitary adenoma, spermatogenesis ceases but can be restored by administration of hCG alone [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/56\">",
"     56",
"    </a>",
"    ]. In normal men in whom FSH is selectively suppressed by administration of testosterone and hCG, sperm production is approximately one-half of normal but can be increased to normal by administration of FSH [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/57\">",
"     57",
"    </a>",
"    ]. These data suggest that both LH and FSH are necessary for the initiation of spermatogenesis, that LH by itself is sufficient for reinitiation and maintenance of spermatogenesis in adulthood, but that FSH is also necessary for spermatogenesis to be quantitatively normal in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intratesticular paracrine factors and regulation of spermatogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary function of the Sertoli cell barrier of tight junctions between the spermatogonia and primary spermatocyte is probably to maintain proper conditions for germ cell development in the tubules (",
"    <a class=\"graphic graphic_figure graphicRef69256 \" href=\"UTD.htm?5/19/5430\">",
"     figure 1",
"    </a>",
"    ). Some molecules such as glucose and testosterone penetrate the tubule readily, whereas large molecules and peptides are almost completely excluded. Peptide hormones secreted into the tubular lumen are retained there by the barrier and may not function as endocrine factors outside the testis. Because the Sertoli cell barrier prevents many regulatory factors from entering the seminiferous tubules to influence germ cell development directly, the testes must produce local",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    regulatory substances [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/58\">",
"     58",
"    </a>",
"    ]. Factors that influence spermatogenesis include neuropeptides, vasoactive peptides, growth factors, and immune-derived cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/29,59,60\">",
"     29,59,60",
"    </a>",
"    ]. The large number of testicular cell types, the bicompartmental organization of the testis, and the many factors known to be present have led to the belief that coordination of the two functions of the testis (steroid hormone synthesis and spermatogenesis) utilize communication strategies involving the unique anatomic features of the testis. However, most of the paracrine-autocrine effects are postulated on in vitro studies and may not apply to the intact organism [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TESTICULAR FUNCTION DURING DIFFERENT PHASES OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinct phases of male sexual life&mdash;fetal, neonatal, pubertal, and adult&mdash;can be defined in terms of the plasma testosterone level. In the fetal phase, testosterone production by the testes commences during the seventh week of gestation, and serum testosterone concentrations reach 300 to 400",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (10.4 to 13.9",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    which are maintained through the second trimester then fall, so that at the time of birth serum testosterone is similar in males and females.",
"   </p>",
"   <p>",
"    During the neonatal phase, serum testosterone rises in the male and remains elevated for three to six months, again falling to a low level by one year of age and remaining low until the pubertal phase when it rises and reaches adult levels by age 17 (300 to 1000",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [10.4 to 34.7",
"    <span class=\"nowrap\">",
"     nmol/L]).",
"    </span>",
"    The neonatal surge in testosterone secretion results from a rise in plasma LH levels. Inhibin B levels also rise during the neonatal period and reach concentrations exceeding those in normal adults [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31800/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During adulthood, sexual maturation of the male is complete, and sperm production is sufficient to allow reproduction to take place. The serum concentration of bioavailable testosterone remains constant until the fifth decade when it begins to decline at a rate of about 1.2 percent per year; however, total testosterone levels do not decline appreciably until later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physiologic events during these various phases differ, as do the pathologic consequences of derangements in testicular function. Male phenotypic sex differentiation takes place during the fetal phase of male sexual life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"     \"Normal sexual differentiation\"",
"    </a>",
"    .) The role of the neonatal surge in testosterone production is not certain but may involve the imprinting of male gender identity. The roles of testosterone in male puberty and the evaluation of testicular function in adult men are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The testes contain two anatomical units: the spermatogenic tubules, composed of germ cells and Sertoli cells, and the interstitium, containing Leydig cells that produce androgens. The testes are stimulated by luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the gonadotroph cells of the pituitary, and they in turn are stimulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus.",
"   </p>",
"   <p>",
"    The hypothalamus communicates with the pituitary via a portal vascular system and by neural pathways. The preoptic area and the medial basal region of the hypothalamus contain neurons that secrete GnRH in a pulsatile fashion, the so-called GnRH pulse generator. This elicits pulsatile secretion of LH and FSH by the gonadotroph cells of the anterior pituitary.",
"   </p>",
"   <p>",
"    LH stimulates testosterone synthesis, and FSH regulates spermatogenesis.",
"   </p>",
"   <p>",
"    Testosterone can be converted to 5-alpha-dihydrotestosterone, which mediates many of the differentiative, growth-promoting, and functional aspects of androgen action in males. Alternatively, testosterone can be aromatized to estradiol, which exerts effects that are independent of, opposite to, or synergistic to those of androgens.",
"   </p>",
"   <p>",
"    Of the 50 mcg of estradiol formed daily in normal adult men, about 85 percent is synthesized in extraglandular tissues, and the remainder in the testes.",
"   </p>",
"   <p>",
"    Gonadal steroids are transported in the plasma largely bound to albumin and sex hormone-binding globulin (SHBG, also called testosterone-binding globulin or TeBG). In normal men, approximately 2 percent of plasma testosterone is free or unbound, 44 percent is bound to SHBG, and 54 percent is bound to albumin and other proteins.",
"   </p>",
"   <p>",
"    As described above, the physiological actions of testosterone are the result of the combined effects of testosterone itself plus its active androgenic and estrogen metabolites. The major functions of androgens in males include (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Androgen action'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Regulation of gonadotropin secretion by the hypothalamic-pituitary system",
"     </li>",
"     <li>",
"      Initiation and maintenance of spermatogenesis",
"     </li>",
"     <li>",
"      Formation of the male phenotype during embryogenesis",
"     </li>",
"     <li>",
"      Promotion of sexual maturation at puberty and its maintenance thereafter",
"     </li>",
"     <li>",
"      Increase in lean body mass and decrease in fat mass",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/1\">",
"      Wong CH, Cheng CY. The blood-testis barrier: its biology, regulation, and physiological role in spermatogenesis. Curr Top Dev Biol 2005; 71:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/2\">",
"      Krsmanovic LZ, Hu L, Leung PK, et al. The hypothalamic GnRH pulse generator: multiple regulatory mechanisms. Trends Endocrinol Metab 2009; 20:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/3\">",
"      Conn PM. The molecular basis of gonadotropin-releasing hormone action. Endocr Rev 1986; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/4\">",
"      Dufau ML, Catt KJ. Gonadotropin receptors and regulation of steroidogenesis in the testis and ovary. Vitam Horm 1978; 36:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/5\">",
"      Wahlstr&ouml;m T, Huhtaniemi I, Hovatta O, Sepp&auml;l&auml; M. Localization of luteinizing hormone, follicle-stimulating hormone, prolactin, and their receptors in human and rat testis using immunohistochemistry and radioreceptor assay. J Clin Endocrinol Metab 1983; 57:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/6\">",
"      Means AR, Fakunding JL, Huckins C, et al. Follicle-stimulating hormone, the Sertoli cell, and spermatogenesis. Recent Prog Horm Res 1976; 32:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/7\">",
"      Hayes FJ, DeCruz S, Seminara SB, et al. Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J Clin Endocrinol Metab 2001; 86:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/8\">",
"      Santen, RJ. Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men? J Clin Invest 1975; 56:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/9\">",
"      Hayes FJ, Seminara SB, Decruz S, et al. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 2000; 85:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/10\">",
"      Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/11\">",
"      Matsumoto AM, Bremner WJ. Modulation of pulsatile gonadotropin secretion by testosterone in man. J Clin Endocrinol Metab 1984; 58:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/12\">",
"      Veldhuis JD, Rogol AD, Samojlik E, Ertel NH. Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man. J Clin Invest 1984; 74:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/13\">",
"      Sheckter CB, Matsumoto AM, Bremner WJ. Testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary. J Clin Endocrinol Metab 1989; 68:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/14\">",
"      McLachlan RI, Matsumoto AM, Burger HG, et al. Relative roles of follicle-stimulating hormone and luteinizing hormone in the control of inhibin secretion in normal men. J Clin Invest 1988; 82:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/15\">",
"      Majumdar SS, Mikuma N, Ishwad PC, et al. Replacement with recombinant human inhibin immediately after orchidectomy in the hypophysiotropically clamped male rhesus monkey (Macaca mulatta) maintains follicle-stimulating hormone (FSH) secretion and FSH beta messenger ribonucleic acid levels at precastration values. Endocrinology 1995; 136:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/16\">",
"      Anawalt BD, Bebb RA, Matsumoto AM, et al. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 1996; 81:3341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/17\">",
"      O'Connor AE, De Kretser DM. Inhibins in normal male physiology. Semin Reprod Med 2004; 22:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/18\">",
"      Andersson AM, Skakkebaek NE. Serum inhibin B levels during male childhood and puberty. Mol Cell Endocrinol 2001; 180:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/19\">",
"      Williams CL, Nishihara M, Thalabard JC, et al. Corticotropin-releasing factor and gonadotropin-releasing hormone pulse generator activity in the rhesus monkey. Electrophysiological studies. Neuroendocrinology 1990; 52:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/20\">",
"      Refojo D, Arias P, Moguilevsky JA, Feleder C. Effect of bacterial endotoxin on in vivo pulsatile gonadotropin secretion in adult male rats. Neuroendocrinology 1998; 67:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/21\">",
"      Baigrie RJ, Lamont PM, Kwiatkowski D, et al. Systemic cytokine response after major surgery. Br J Surg 1992; 79:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/22\">",
"      Roubenoff R, Grinspoon S, Skolnik PR, et al. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab 2002; 283:E138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/23\">",
"      Chan JL, Heist K, DePaoli AM, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003; 111:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/24\">",
"      Stocco DM, Clark BJ. The role of the steroidogenic acute regulatory protein in steroidogenesis. Steroids 1997; 62:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/25\">",
"      Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1988; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/26\">",
"      Auchus RJ, Gupta MK. Towards a unifying mechanism for CYP17 mutations that cause isolated 17,20-lyase deficiency. Endocr Res 2002; 28:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/27\">",
"      Winters SJ, Troen P. Testosterone and estradiol are co-secreted episodically by the human testis. J Clin Invest 1986; 78:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/28\">",
"      Axelsson J, Ingre M, Akerstedt T, Holmb&auml;ck U. Effects of acutely displaced sleep on testosterone. J Clin Endocrinol Metab 2005; 90:4530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/29\">",
"      Saez JM. Leydig cells: endocrine, paracrine, and autocrine regulation. Endocr Rev 1994; 15:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/30\">",
"      Federman DD. The biology of human sex differences. N Engl J Med 2006; 354:1507.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson JD. Metabolism of testicular androgens. In: Handbook of Physiology; Section 7: Endocrinology, Greep RO, Astwood EB (Eds), American Physiological Society, Washington, DC 1975. Vol V: Male Reproductive System, p.491.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/32\">",
"      Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63:25.",
"     </a>",
"    </li>",
"    <li>",
"     Griffin JE, McPhaul MJ, Russell DW, Wilson JD. The androgen resistance syndromes: Steroid 5-alpha-reductase 2 deficiency, testicular feminization, and related disorders. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.4117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/34\">",
"      Mahendroo MS, Cala KM, Hess DL, Russell DW. Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes. Endocrinology 2001; 142:4652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/35\">",
"      Mahendroo MS, Mendelson CR, Simpson ER. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J Biol Chem 1993; 268:19463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/36\">",
"      Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/37\">",
"      Pardridge WM, Landaw EM. Testosterone transport in brain: primary role of plasma protein-bound hormone. Am J Physiol 1985; 249:E534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/38\">",
"      Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004; 7:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/39\">",
"      Claessens F, Denayer S, Van Tilborgh N, et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 2008; 6:e008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/40\">",
"      Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/41\">",
"      Gao T, Marcelli M, McPhaul MJ. Transcriptional activation and transient expression of the human androgen receptor. J Steroid Biochem Mol Biol 1996; 59:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/42\">",
"      Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/43\">",
"      Lee DK, Chang C. Molecular communication between androgen receptor and general transcription machinery. J Steroid Biochem Mol Biol 2003; 84:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/44\">",
"      Rahman F, Christian HC. Non-classical actions of testosterone: an update. Trends Endocrinol Metab 2007; 18:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/45\">",
"      Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol 2008; 29:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/46\">",
"      Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendocrinol 2008; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/47\">",
"      Walker WH. Molecular mechanisms of testosterone action in spermatogenesis. Steroids 2009; 74:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/48\">",
"      Johnson L, Petty CS, Neaves WB. Further quantification of human spermatogenesis: germ cell loss during postprophase of meiosis and its relationship to daily sperm production. Biol Reprod 1983; 29:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/49\">",
"      Buaas FW, Kirsh AL, Sharma M, et al. Plzf is required in adult male germ cells for stem cell self-renewal. Nat Genet 2004; 36:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/50\">",
"      Costoya JA, Hobbs RM, Barna M, et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 2004; 36:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/51\">",
"      Lie PP, Cheng CY, Mruk DD. Coordinating cellular events during spermatogenesis: a biochemical model. Trends Biochem Sci 2009; 34:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/52\">",
"      Wang C, McDonald V, Leung A, et al. Effect of increased scrotal temperature on sperm production in normal men. Fertil Steril 1997; 68:334.",
"     </a>",
"    </li>",
"    <li>",
"     DeKrestser DM, Riskbridger GP, Kerr JB. Basic endocrinology of the testis. In: Endocrinology, 3rd, de Groot LJ (Ed), WB Saunders, Philadelphia 1996. p.2307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/54\">",
"      De Gendt K, Swinnen JV, Saunders PT, et al. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A 2004; 101:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/55\">",
"      Matthiesson KL, McLachlan RI, O'Donnell L, et al. The relative roles of follicle-stimulating hormone and luteinizing hormone in maintaining spermatogonial maturation and spermiation in normal men. J Clin Endocrinol Metab 2006; 91:3962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/56\">",
"      Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N Engl J Med 1985; 313:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/57\">",
"      Matsumoto AM, Karpas AE, Bremner WJ. Chronic human chorionic gonadotropin administration in normal men: evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man. J Clin Endocrinol Metab 1986; 62:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/58\">",
"      Pescovitz OH, Srivastava CH, Breyer PR, Monts BA. Paracrine control of spermatogenesis. Trends Endocrinol Metab 1994; 5:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/59\">",
"      Gnessi L, Fabbri A, Spera G. Gonadal peptides as mediators of development and functional control of the testis: an integrated system with hormones and local environment. Endocr Rev 1997; 18:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/60\">",
"      Sofikitis N, Giotitsas N, Tsounapi P, et al. Hormonal regulation of spermatogenesis and spermiogenesis. J Steroid Biochem Mol Biol 2008; 109:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31800/abstract/61\">",
"      Huleihel M, Abuelhija M, Lunenfeld E. In vitro culture of testicular germ cells: regulatory factors and limitations. Growth Factors 2007; 25:236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7474 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31800=[""].join("\n");
var outline_f31_3_31800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE OF THE TESTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE HYPOTHALAMIC-PITUITARY-TESTICULAR AXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GnRH actions in the pituitary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gonadotropin actions in the testes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Feedback control of gonadotropin secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANDROGEN SYNTHESIS, TRANSPORT, METABOLISM, AND ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Androgen synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Testosterone metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transport of gonadal steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Androgen action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Classical pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Non-classical pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPERMATOGENESIS AND ITS REGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hormonal control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intratesticular paracrine factors and regulation of spermatogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TESTICULAR FUNCTION DURING DIFFERENT PHASES OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7474|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/19/5430\" title=\"figure 1\">",
"      Seminiferous epithelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/43/14002\" title=\"figure 2\">",
"      Hypo pit testic axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/58/20398\" title=\"figure 3\">",
"      Continuous GnRH LH and FSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/20/40271\" title=\"figure 4\">",
"      Testost formation metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/56/35724\" title=\"figure 5\">",
"      Androgen receptor domains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/40/39567\" title=\"figure 6\">",
"      Cell divisions spermatogenesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=related_link\">",
"      Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=related_link\">",
"      Hypothalamic-pituitary axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=related_link\">",
"      Normal sexual differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=related_link\">",
"      Steroid 5-alpha-reductase 2 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31801="Resuscitative thoracotomy: technique";
var content_f31_3_31801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Resuscitative thoracotomy: technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31801/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31801/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31801/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31801/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31801/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31801/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/3/31801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1247118515\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitative thoracotomy is a procedure of last resort that is performed only under specific clinical circumstances. Resuscitative thoracotomy is nearly always performed in the emergency department and involves gaining rapid access to the heart and major thoracic vessels through an anterolateral chest incision to control exsanguinating hemorrhage or other life-threatening chest injuries. The first successful resuscitative thoracotomy was described for the resuscitation of a patient with penetrating cardiac injury and this indication remains the one associated with the highest rate of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will briefly review the indications for resuscitative (emergency) thoracotomy, which are discussed more fully in separate reviews, and discuss the technique of resuscitative thoracotomy. The initial resuscitation, diagnostic evaluation, and management of the trauma patient with blunt or penetrating trauma is based upon protocols from the Advanced Trauma Life Support (ATLS&reg;) program established by the American College of Surgeons Committee on Trauma. The initial evaluation and resuscitation of the patient with blunt or penetrating abdominal or thoracic trauma is discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"       \"Prehospital care of the adult trauma patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"       \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"       \"Initial evaluation and management of abdominal stab wounds in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197313272\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR THORACOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitative thoracotomy is restricted to patients with specific indications as determined by the patient's clinical status en route and immediately upon arrival to the emergency department, the mechanism of injury, or the need to perform therapeutic maneuvers to manage correctable causes of shock, including decompressing cardiac tamponade, cross-clamping the aorta, managing exsanguinating cardiac or vascular injuries, and evacuating air embolism. (See",
"    <a class=\"local\" href=\"#H1247118616\">",
"     'Aortic cross-clamping'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H108022308\">",
"     'Pericardiotomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1247118637\">",
"     'Hemorrhage control and repair'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1247118651\">",
"     'Identifying and evacuating air embolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24289990\">",
"    <span class=\"h2\">",
"     Penetrating injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitative thoracotomy is justified in patients with penetrating thoracic trauma who are hemodynamically unstable on arrival to the emergency department despite appropriate fluid resuscitation, or in patients who have been pulseless for less than 15 minutes, but only if appropriate resources (eg, operating room, appropriately-trained surgeon) are available for continued resuscitation and definitive repair. The rationale for resuscitative thoracotomy in penetrating injury is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H4933905#H4933905\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Emergency department thoracotomy (EDT)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197314164\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitative thoracotomy is likely to be futile in patients with penetrating injury in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has no pulse or blood pressure in the field",
"     </li>",
"     <li>",
"      Asystole is the presenting rhythm and there is no pericardial tamponade",
"     </li>",
"     <li>",
"      Prolonged pulselessness (&gt;15 minutes) occurs at any time",
"     </li>",
"     <li>",
"      Massive, nonsurvivable injuries have occurred",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24290008\">",
"    <span class=\"h2\">",
"     Blunt injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subset of patients with blunt injury who might benefit from resuscitative thoracotomy includes patients who lose vital signs and have no obvious non-survivable injury (eg, massive head trauma, multiple severe injuries), or patients with cardiac tamponade rapidly diagnosed by ultrasound, with no obvious non-survivable injury, but only if appropriate resources (eg, operating room, appropriately-trained surgeon) are available for continued resuscitation and definitive repair. These indications are discussed in detail elsewhere (",
"    <a class=\"graphic graphic_algorithm graphicRef81674 \" href=\"UTD.htm?38/36/39489\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Emergent thoracotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thoracic aortic cross-clamping prior to abdominal exploration may benefit a subset of patients with penetrating abdominal injury and exsanguinating hemorrhage. Retrospective reviews report survival that ranges from 14 to 42 percent in patients with severe penetrating abdominal injuries who underwent thoracic aortic clamping prior to abdominal exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, controlled comparisons are lacking. In one of these reviews, hemorrhagic shock was due to major abdominal vascular (75 percent) or severe liver (25 percent) injuries, and all required massive blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/4\">",
"     4",
"    </a>",
"    ]. Sixteen percent of the patients survived hospitalization neurologically intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24290614\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with blunt injury, resuscitative thoracotomy is likely to be futile if:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient required &gt;15 minutes of prehospital CPR",
"     </li>",
"     <li>",
"      The patient is apneic, pulseless, and has no rhythm on cardiac monitor in the field",
"     </li>",
"     <li>",
"      The patient has massive, non-survivable injuries",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247118564\">",
"    <span class=\"h1\">",
"     THORACIC ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thorax is the area of the body between the base of the neck superiorly, and the diaphragm inferiorly. The thorax contains the heart, lungs and major vascular structures including the aorta, arch vessels (brachiocephalic, carotid, and subclavian arteries), and descending thoracic aorta. The descending thoracic aorta is covered by a thin layer of parietal pleura that must be divided to expose the aorta.",
"   </p>",
"   <p>",
"    The aortic root is a midline structure and the heart is normally positioned in the left chest with the apex of the left ventricle at the left mid-clavicular line. The arch of the aorta sweeps from the midline posteriorly to the left, and the descending thoracic aorta lays adjacent the spine (",
"    <a class=\"graphic graphic_figure graphicRef86026 \" href=\"UTD.htm?23/38/24168\">",
"     figure 1",
"    </a>",
"    ). The arch of the aorta and great vessels are located beneath the manubrium of the sternum.",
"   </p>",
"   <p>",
"    Normal arch anatomy consists of three branches; the brachiocephalic trunk, which gives off the right common carotid and right subclavian arteries; the left common carotid artery; and the left subclavian artery. Variations of the aortic arch (",
"    <a class=\"graphic graphic_figure graphicRef54048 \" href=\"UTD.htm?5/47/5878\">",
"     figure 2",
"    </a>",
"    ) occur in about 17 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The most common variation is a bovine arch with the left common carotid artery arising from a larger than usual brachiocephalic trunk.",
"   </p>",
"   <p>",
"    The pericardial sac surrounds and protects the heart. The left phrenic and vagus nerves pass anterior to the aortic arch in proximity to the origin of the left subclavian artery. The left phrenic nerve is adherent to the lateral surface of the pericardium (",
"    <a class=\"graphic graphic_figure graphicRef52752 \" href=\"UTD.htm?16/21/16725\">",
"     figure 3",
"    </a>",
"    ) and is particularly susceptible to inadvertent injury during resuscitative thoracotomy. The left vagus nerve gives rise to the left recurrent laryngeal nerve, which encircles the aortic arch just medial to the origin of the left subclavian artery. The left vagus nerve travels posterior to the root of the left lung and then adjacent the esophagus as it descends in the posterior mediastinum. Due to its posterior location, it is less vulnerable to injury compared with the phrenic nerve.",
"   </p>",
"   <p>",
"    The esophagus is located on the anterior surface of the spine and medial to the aorta. The thoracic duct ascends along the anterolateral surface of the spine, is virtually invisible, and is susceptible to traumatic avulsion that can result in chylothorax. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247118578\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision has been made to open the chest, one member of the trauma team should be designated to lead the ongoing resuscitation effort while an experienced member of the trauma team is performing the thoracotomy.",
"   </p>",
"   <p>",
"    While intubation and large-bore intravenous access are underway, patients with penetrating injuries should be completely disrobed and quickly rolled in both directions to locate all entrance and exit wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/9\">",
"     9",
"    </a>",
"    ]. A nasogastric or orogastric tube should be placed to aid localization when clamping the aorta. (See",
"    <a class=\"local\" href=\"#H1247118616\">",
"     'Aortic cross-clamping'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prior to resuscitative thoracotomy, a right chest tube should ideally be placed prophylactically in the event of inadvertent entry into the right pleural space. Practically speaking, it may also be placed by another member of the trauma team simultaneous with the thoracotomy procedure. &nbsp;",
"   </p>",
"   <p>",
"    The patient is positioned supine, with the arms placed overhead or on arm boards laterally if extremity injuries are present. The skin is quickly prepared using iodine solution poured over the entire thorax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24289882\">",
"    <span class=\"h2\">",
"     Equipment and supplies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sterile thoracotomy tray should be available in the trauma room at all times. The tray should include sterile drapes and towels, laparotomy sponges and gauze pads, and appropriate instruments (",
"    <a class=\"graphic graphic_table graphicRef86656 \" href=\"UTD.htm?33/22/34155\">",
"     table 1",
"    </a>",
"    ) including a scalpel holder and scalpel blades, scissors, rib spreader, aortic cross clamps, a variety of other hemostatic clamps, tissue forceps, sutures, Teflon pledgets and needle drivers. A separate Foley catheter (5 cc balloon) should also be available for temporizing control of hemorrhage. (See",
"    <a class=\"local\" href=\"#H1247118637\">",
"     'Hemorrhage control and repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4649316\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are recommended prior to cardiothoracic surgery (",
"    <a class=\"graphic graphic_table graphicRef87205 \" href=\"UTD.htm?26/48/27404\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4649357\">",
"    <span class=\"h2\">",
"     Universal precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitative thoracotomy is associated with a significant blood splatter in often unpredictable directions. Given the increased of risk of exposure to blood-borne disease in the trauma setting, we agree with ATLS recommendations that all personnel involved in the care of the trauma patient should observe universal precautions wearing gowns, gloves and eye protection at all times. Any personnel not immediately involved in the thoracotomy procedure should stand away from the table to minimize their risk of exposure. After the procedure is completed, particular care should be exercised with disposal of instruments, particularly sharps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=see_link\">",
"     \"Operating room safety\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\", section on 'Epidemiology of bloodborne exposures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased prevalence of blood-borne pathogens such as Human Immunodeficiency Virus (HIV) and Hepatitis B (Hep B) or Hepatitis C (Hep C) in the trauma population is well-known [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/9-17\">",
"     9-17",
"    </a>",
"    ]. The estimated seroprevalence of HIV in injured patients in emergency departments in the United States is between 0.5 and 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/18\">",
"     18",
"    </a>",
"    ]. Hep B and C seroprevalence rates may be higher [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/12,19-21\">",
"     12,19-21",
"    </a>",
"    ]. In one series evaluating these diseases in penetrating trauma patients, the subset of patients most likely to undergo resuscitative thoracotomy, infection with HIV or hepatitis was present in 9.4 percent. The prevalence of HIV was 1.2 percent, the prevalence of Hep B antigen was 0.6 percent, and the prevalence of Hep C was 7.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/12,20,21\">",
"     12,20,21",
"    </a>",
"    ]. The risk of infection following occupational exposure to HIV is relatively low (0.3 percent). Hepatitis is more readily transmitted through occupational exposure with transmission rates for Hep B ranging from 6 to 30 percent and transmission rates for Hep C ranging from 0 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536270443\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the technique of resuscitative thoracotomy is relatively straightforward, the procedure is often performed by those who don&rsquo;t routinely perform elective thoracotomy. A systematic approach can help the practitioner avoid pitfalls and optimize patient outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108024991\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the indications for resuscitative thoracotomy (ie, patient in extremis with loss of vital signs), the steps are generally performed in a defined order, which is discussed in more detail below. However, the clinical presentation of the patient or the nature of a specific injury may make one step take precedence over another. As an example, aortic cross-clamping may take precedence over pericardiotomy in the patient with exsanguinating hemorrhage from an aortic rent. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incision is made, the chest is entered, and a retractor is placed. (See",
"      <a class=\"local\" href=\"#H108020288\">",
"       'Incision'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H108022140\">",
"       'Opening the chest'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Damage control maneuvers are used to manage hemorrhage that will impede performance of pericardiotomy or aortic cross-clamping. (See",
"      <a class=\"local\" href=\"#H108028383\">",
"       'Damage control'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The pericardial sac is opened and temporizing measures are used to control any cardiac injuries, if present. Air embolism is managed if identified. (See",
"      <a class=\"local\" href=\"#H108022308\">",
"       'Pericardiotomy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1247118637\">",
"       'Hemorrhage control and repair'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1247118651\">",
"       'Identifying and evacuating air embolism'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The aorta is cross-clamped to allow filling of the heart and facilitate ongoing fluid resuscitation. (See",
"      <a class=\"local\" href=\"#H1247118616\">",
"       'Aortic cross-clamping'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Open cardiac massage is initiated once the heart has filled sufficiently. (See",
"      <a class=\"local\" href=\"#H1247118630\">",
"       'Open cardiac massage and internal defibrillation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The thoracic structures are systematically explored, looking for any additional bleeding or hematoma formation that might suggest underlying injury. (See",
"      <a class=\"local\" href=\"#H1247118637\">",
"       'Hemorrhage control and repair'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108020288\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A generous, left anterolateral thoracotomy, which exposes the heart, lungs, aortic arch, great vessels, descending aorta and esophagus, is most often chosen. If massive bleeding from a right chest injury is suspected, then an initially right-sided approach may be taken. If needed, the thoracotomy incision can be extended across the sternum to the right (or left) as a clamshell incision, using a Gigli saw or Lebsche knife. A posterolateral thoracotomy approach is",
"    <strong>",
"     not",
"    </strong>",
"    used under emergent circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For anterolateral thoracotomy, the skin incision is made with a #10 blade from the margin of the sternum along the intercostal space between the 4",
"    <sup>",
"     th",
"    </sup>",
"    and 5",
"    <sup>",
"     th",
"    </sup>",
"    ribs (4",
"    <sup>",
"     th",
"    </sup>",
"    interspace), or 5",
"    <sup>",
"     th",
"    </sup>",
"    and 6",
"    <sup>",
"     th",
"    </sup>",
"    ribs (5",
"    <sup>",
"     th",
"    </sup>",
"    interspace) (",
"    <a class=\"graphic graphic_figure graphicRef86029 \" href=\"UTD.htm?8/12/8389\">",
"     figure 4",
"    </a>",
"    ), below the nipple and carried laterally to the left posterior axillary line, following the curve of the rib. In the female patient, the breast should be retracted superiorly. The skin and subcutaneous fat are incised sharply with the scalpel. In thin patients, the initial incision can be carried directly down to one of the ribs.",
"   </p>",
"   <p>",
"    For patients who arrive in the emergency department with an offending penetrating object (eg, knife blade) in situ, the object should generally be left in place, unless it interferes with performing the thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108022140\">",
"    <span class=\"h2\">",
"     Opening the chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic cavity is entered laterally (away from the heart) by making a small (1 to 2 cm) incision along the superior margin of the underlying rib to avoid injury to the intercostal neurovascular bundle, which is located along the inferior margin of the rib (",
"    <a class=\"graphic graphic_figure graphicRef59415 \" href=\"UTD.htm?23/32/24069\">",
"     figure 5",
"    </a>",
"    ). The pleura immediately beneath the muscles is likewise divided, taking care not injure the lung. Once the chest is entered, a curved Mayo scissors (or sterile trauma shears) is placed into the wound and pushed anteriorly toward the sternum to open the interspace by shearing the intercostal muscles from the rib (",
"    <a class=\"graphic graphic_figure graphicRef86029 \" href=\"UTD.htm?8/12/8389\">",
"     figure 4",
"    </a>",
"    ). To complete the incision, the scissors is pushed to the posterior axillary line. In the posterior direction, this technique may be easily accomplished and the intercostals can be divided close to the superior margin of the rib using the scissors. Alternatively, instead of shearing the muscles from the rib using the Mayo scissors, the interspace can be bluntly distracted by placing one or two fingers of each hand into the initial defect, pulling caudally with the left hand and cranially with right hand.",
"   </p>",
"   <p>",
"    After entering the chest, a rib spreader (Finochietto) is inserted between the ribs with the arm of the retractor directed towards the left axilla, permitting extension of the incision across the sternum for additional exposure, if necessary, without the need to replace the retractor. The retractor should be opened as wide as possible to maximize exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108028383\">",
"    <span class=\"h2\">",
"     Damage control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the chest is opened, the anesthesiologist or respiratory therapist should stop ventilating the left lung to allow it to collapse, facilitating exposure. In the emergency setting, one-lung ventilation may be difficult to achieve but may be accomplished by pushing the endotracheal tube beyond the carina into the mainstem right (left) bronchus. The surgeon can facilitate this by occluding the ipsilateral mainstem bronchus.",
"   </p>",
"   <p>",
"    Bleeding that will hinder pericardiotomy or aortic cross-clamping needs to be managed first. Bleeding from non-cardiac sites can be controlled using a combination of direct pressure using laparotomy pads or sponge sticks, or direct clamping with a vascular clamp. Significant hemorrhage originating from the pulmonary parenchyma or major pulmonary vasculature can be controlled with direct clamping of the injured lung tissue (Duval clamp) or vessel, clamping the pulmonary hilum, or by using the &ldquo;pulmonary hilar twist&rdquo; maneuver (",
"    <a class=\"graphic graphic_figure graphicRef86030 \" href=\"UTD.htm?5/12/5320\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/25\">",
"     25",
"    </a>",
"    ]. Pulmonary hilar clamping and the &ldquo;pulmonary hilar twist&rdquo; also reduce the potential for ongoing air embolism.",
"   </p>",
"   <p>",
"    To perform hilar clamping or the &ldquo;pulmonary hilar twist,&rdquo; the injured lung hilum is mobilized by dividing the inferior pulmonary ligament to the level of the inferior pulmonary vein (",
"    <a class=\"graphic graphic_figure graphicRef86030 \" href=\"UTD.htm?5/12/5320\">",
"     figure 6",
"    </a>",
"    ). The hilum of the lung can be controlled with a large vascular clamp (eg, Crawford or Satinsky) or using a Rommel tourniquet and snares [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/26\">",
"     26",
"    </a>",
"    ]. For the pulmonary twist maneuver, the lower lobe is rotated anteriorly over the upper lobe twisting the lung clockwise 180&deg;, which compresses the main pulmonary artery and vein against the bronchus [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/25\">",
"     25",
"    </a>",
"    ]. Care should be taken not to extend or create new injuries by over-twisting. To prevent the lung from untwisting, laparotomy packs are placed at the base and apex of the lung.",
"   </p>",
"   <p>",
"    Prolonged hilar control (clamp or twist) can lead to complications such as right heart failure, dysrhythmias, and hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. As such, the duration of time the hilum is clamped or twisted should be limited, and pulmonary injuries identified and definitively managed as soon as is feasible. For some patients, the ongoing resuscitative effort is prolonged due to hypothermia, coagulopathy, and acidosis. In these patients, prolonged hilar control commits the patient to pneumonectomy. The hilum should remain clamped or twisted until pulmonary resection can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108022308\">",
"    <span class=\"h2\">",
"     Pericardiotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step in a resuscitative thoracotomy is pericardiotomy. If there is no pericardial tamponade and other obvious non-cardiac injuries are apparent, it is acceptable to leave the pericardium closed to address these injuries first. Open cardiac massage can be performed with the pericardium intact.",
"   </p>",
"   <p>",
"    If there are no other obvious injuries and the myocardium cannot be seen through the pericardium, the pericardium should be opened. The phrenic nerve is identified on the anterolateral surface of the pericardium and protected from injury (",
"    <a class=\"graphic graphic_figure graphicRef86031 \" href=\"UTD.htm?42/31/43505\">",
"     figure 7",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1247118564\">",
"     'Thoracic anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The pericardium is grasped with a toothed forceps (",
"    <a class=\"graphic graphic_picture graphicRef62808 \" href=\"UTD.htm?22/16/22789\">",
"     picture 1",
"    </a>",
"    ) and the pericardial sac entered through a small incision anterior to the phrenic nerve using a knife or Metzenbaum scissors. The pericardiotomy is extended parallel (not perpendicular) to the phrenic nerve superiorly and inferiorly from the initial incision (",
"    <a class=\"graphic graphic_figure graphicRef86031 \" href=\"UTD.htm?42/31/43505\">",
"     figure 7",
"    </a>",
"    ) using a Metzenbaum scissors to expose the heart and great vessels. Pericardial fluid and any blood clots are evacuated, and the heart and great vessels are inspected. The heart is then delivered from the pericardial sac, inspected on its surface for any wounds, and gently palpated. Any bleeding is controlled initially with digital compression. (See",
"    <a class=\"local\" href=\"#H1247118637\">",
"     'Hemorrhage control and repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247118616\">",
"    <span class=\"h2\">",
"     Aortic cross-clamping",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic aorta is typically cross-clamped to redistribute the available intravascular blood volume to the myocardium and brain, which effectively doubles the mean arterial pressure and cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/1,5,6,29-33\">",
"     1,5,6,29-33",
"    </a>",
"    ]. For patients with concomitant abdominal injuries, this maneuver also reduces subdiaphragmatic blood loss.",
"   </p>",
"   <p>",
"    To perform aortic cross clamping, the left lung is retracted superiorly, and the inferior pulmonary ligament is divided. The orogastric or nasogastric tube should be palpated to differentiate the esophagus from the empty descending aorta. Dissection should be performed at the level of an inter-vertebral space in a plane perpendicular to the aorta to avoid injury to intercostals vessels, which branch from the aorta at the level of the mid-vertebral body (",
"    <a class=\"graphic graphic_figure graphicRef86032 \" href=\"UTD.htm?13/41/13970\">",
"     figure 8",
"    </a>",
"    ). The parietal pleura overlying the aorta are incised, and the tissues between the aorta and esophagus, as well as the prevertebral fascia, are separated to create sufficient space to place the aortic clamp without avulsing the intercostal arteries from the posterior surface of the aorta.",
"   </p>",
"   <p>",
"    The aorta is ideally clamped just above the diaphragm (",
"    <a class=\"graphic graphic_picture graphicRef50029 \" href=\"UTD.htm?8/53/9047\">",
"     picture 2",
"    </a>",
"    ) to maximize spinal cord perfusion, but the aorta can also be clamped just below the left pulmonary hilum.",
"    <strong>",
"    </strong>",
"    For patients with abdominal injuries who survive the initial emergency department resuscitative efforts, the thoracic aortic cross-clamp should be repositioned lower on the abdominal aorta whenever possible. Prolonged clamping more than 30 minutes cranial to the visceral vessels worsens already poor outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=see_link&amp;anchor=H108749231#H108749231\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Aortic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247118630\">",
"    <span class=\"h2\">",
"     Open cardiac massage and internal defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the pericardium has been opened, Advanced Trauma Life Support (ATLS) and Advanced Cardiac Life Support (ACLS) protocols are continued with open cardiac massage and internal defibrillation, as needed.",
"   </p>",
"   <p>",
"    Cardiac massage should be started immediately after placement of the thoracic aortic clamp and should only be delivered with a two-hand (\"clapping\") technique (",
"    <a class=\"graphic graphic_figure graphicRef86033 \" href=\"UTD.htm?37/62/38895\">",
"     figure 9",
"    </a>",
"    ). The wrists of the caregiver are placed together at the apex of the heart, and the heart is squeezed together between the two open palms in a rhythmic motion. The thumb of each hand is maintained adjacent the first finger to avoid inadvertently pushing them into the heart.",
"   </p>",
"   <p>",
"    Open cardiac massage is superior to closed chest compressions in maintaining cardiac output and providing cerebral and coronary perfusion in animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. External compressions provide approximately 25 percent of baseline cardiac output, resulting in only 10 percent of normal cerebral and coronary flow, whereas open cardiac massage generates 60 to 70 percent of baseline cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/35,38\">",
"     35,38",
"    </a>",
"    ]. In a small study of 10 patients who all underwent closed chest compressions followed by open chest cardiac massage, coronary perfusion pressures were 400 percent greater with open cardiac massage [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients in ventricular fibrillation, internal cardiac defibrillation is performed with the defibrillator initially set at 10 joules. Repeat defibrillation is performed, as needed, at 10 to 50 joules. One of the internal paddles is placed on the anterior (ventral) surface of the heart and the other is placed on the posterior (dorsal) surface of the heart. As with external defibrillation, all personnel should be well away from the patient prior to defibrillation to prevent inadvertent electric shock and avoid blood splatter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247118637\">",
"    <span class=\"h2\">",
"     Hemorrhage control and repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is controlled in a systematic fashion first by identifying and controlling bleeding from the heart, followed by controlling bleeding from major vascular structures of the chest and lungs. The extent to which temporizing repair can be performed during resuscitative thoracotomy depends upon the experience of the operator.",
"   </p>",
"   <p>",
"    Patients who are most likely to be saved with a resuscitative thoracotomy are those sustaining stab wounds to the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. If blood comes jetting out of the heart with pericardiotomy, the first maneuver is direct digital pressure on the cardiac defect. Small wounds may be amenable to definitive suture repair in the emergency department by appropriately-trained personnel, but it is more common for temporizing measures to be instituted in the emergency department until definitive repair can be undertaken in the operating room where adequate lighting, proper instrumentation and materials, and appropriate nursing and support staff are available.",
"   </p>",
"   <p>",
"    Temporizing maneuvers may include direct digital pressure on the wound while the patient is transported to the operating room, stapling the cardiac wound closed using a skin stapler with care to avoid the coronary arteries, or suturing the cardiac wound closed. Suture repair of ventricular cardiac injuries is accomplished using double-armed polypropylene (eg, Prolene), preferably on a cardiovascular (CV) needle. Interrupted 3-0 sutures are placed in a horizontal mattress fashion with pledgets. The suture is passed into the cardiac tissue on each side of the hole parallel to the finger that is providing vascular control (z-stitch), and the pledgets are seated onto the tissue (",
"    <a class=\"graphic graphic_figure graphicRef86034 \" href=\"UTD.htm?24/9/24722\">",
"     figure 10",
"    </a>",
"    ). As the finger is carefully withdrawn, an assistant gently pulls up on the suture, crossing the ends. Additional sutures are placed, as needed, prior to tying the sutures. Venous and atrial wounds can be repaired in a simple, running fashion using 3-0 or 4-0 sutures.",
"   </p>",
"   <p>",
"    If larger defects are present and prove difficult to control or repair, balloon occlusion can be used to achieve temporary hemostasis. A clamped bladder catheter (5 cc balloon) can be inserted through the cardiac defect, inflated and then withdrawn to allow the balloon to tamponade the bleeding.",
"   </p>",
"   <p>",
"    Following evaluation and management of any cardiac injuries, attention should be directed toward any remaining bleeding sites in the chest cavity that have not already been temporarily controlled using damage control techniques. In penetrating trauma, missile or implement trajectories are followed looking for great vessel, lung parenchyma, chest wall, and diaphragmatic injuries. As discussed above, vascular and pulmonary injuries can be clamped or direct pressure applied to control bleeding. Laparotomy pads that have controlled bleeding should remain in place until definitive repair can be undertaken in the operating room under optimal circumstances. (See",
"    <a class=\"local\" href=\"#H108028383\">",
"     'Damage control'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247118651\">",
"    <span class=\"h2\">",
"     Identifying and evacuating air embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;After opening the chest and pericardium, the presence of air in the coronary vessels, heart, and possibly the aorta, is diagnostic for air embolism.",
"   </p>",
"   <p>",
"    Treatment of air embolism is focused upon preventing any additional air from entering the circulation, reducing the volume of air that is present with aspiration, and ongoing hemodynamic support [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When air embolism is thought to be due to lung injury, one-lung ventilation should be instituted and the hilum of the injured lung quickly controlled (see",
"    <a class=\"local\" href=\"#H108028383\">",
"     'Damage control'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108028522\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient regains signs of life as a result of resuscitative thoracotomy, the next priority should be immediate transfer of the patient to the operating room for definitive management by a multidisciplinary trauma team (trauma surgery, cardiac surgery, thoracic surgery, vascular surgery). The detailed management of specific injuries is beyond the scope of this topic but can be found in separate topic reviews. Given the need for this level of expertise, we do",
"    <strong>",
"     not",
"    </strong>",
"    advocate undertaking resuscitative thoracotomy in any emergency department where definitive injury management is not immediately available. (See",
"    <a class=\"local\" href=\"#H197313272\">",
"     'Indications for thoracotomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once thoracic, abdominal or other injuries have been adequately addressed in the operating room, the question remains whether to close the chest or to perform temporary closure, as is often performed following damage control laparotomy for trauma. Retrospective reviews have evaluated temporary thoracic closure but have not demonstrated any specific advantage [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In one small study, initial postoperative peak inspiratory pressures were significantly better with temporary closure compared with definitive closure (20 versus 32.5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/45\">",
"     45",
"    </a>",
"    ]. There were no significant differences in the incidence of infectious complications (24 versus 25 percent), hemorrhagic complications (18 versus 14 percent), or survival (47 versus 57 percent) between the two groups.",
"   </p>",
"   <p>",
"    Patients who survive the initial operation are transferred to the intensive care unit for ongoing resuscitation to correct acidosis, coagulopathy, and hypothermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536270528\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data evaluating the outcomes of resuscitative thoracotomy are derived primarily from retrospective reviews and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/2,9,19,47-56\">",
"     2,9,19,47-56",
"    </a>",
"    ]. Studies are generally of low quality with heterogeneity in the population (eg, mechanism, type of injury), and outcomes studied. The largest study of these was a systematic review of 24 nonrandomized studies from 2000 that included 4,620 resuscitative thoracotomies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/19\">",
"     19",
"    </a>",
"    ]. The overall survival rate was 7.4 percent, ranging from 2.5 to 27.5 percent. Factors reported as influencing outcomes were mechanism of injury, location of major injury, and the presence of signs of life. Although survival is possible after resuscitative thoracotomy, up to 7 percent of those who do survive suffer permanent neurologic consequences of prolonged anoxia. Given the poor outcomes associated with resuscitative thoracotomy, accepted criteria by which to perform the procedure have become more restrictive such that reported outcomes since this review have been similar or even better, possibly reflecting a more appropriate selection of patients who are more likely to benefit from the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/2,47-56\">",
"     2,47-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanism of injury is an important factor determining survival following resuscitative thoracotomy. In the systematic review, survival was the highest for isolated penetrating cardiac injuries at 19.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/19\">",
"     19",
"    </a>",
"    ]. Overall survival for thoracic injuries was 10.7 percent compared with 4.5 percent for abdominal injuries and much less for multiple injuries at 0.7 percent. Survival for multiple injuries to the great vessels is essentially zero [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival rates are 37 to 60 percent for penetrating injury, which is much higher compared with blunt injury for which survival is 0 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/47,49,57-61\">",
"     47,49,57-61",
"    </a>",
"    ]. Among penetrating injuries, survival following resuscitative thoracotomy for gunshot wounds is two to four times worse than for stab wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/19,40,41,51,62,63\">",
"     19,40,41,51,62,63",
"    </a>",
"    ]. In the large systematic review, survival rates were 4.3 percent for gunshot wounds and 16.8 percent for stab wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/19\">",
"     19",
"    </a>",
"    ]. Single stab wounds to the epigastrium of the chest wall fared the best.",
"   </p>",
"   <p>",
"    The clinical condition of the patients prior to arrival in the emergency department also impacts survival following resuscitative thoracotomy. The absence of signs of life, which refers to lack of any evidence of cardiac and cerebral perfusion, is associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/52,64\">",
"     52,64",
"    </a>",
"    ]. In one retrospective review, nonreactive pupils were associated with no survival compared with a survival rate of 30 percent for those with reactive pupils. Similarly, one-third of patients with documented spontaneous extremity movement prior to arrival at the hospital survived, whereas none without extremity movement survived [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/64\">",
"     64",
"    </a>",
"    ]. In the systematic review discussed above, survival rates were 11.5 and 8.9 percent if signs of life were present upon arrival to the emergency department or in the field, respectively, compared with 2.6 and 1.2 percent, if they were absent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with documented vital signs (blood pressure, pulse) in the field but who arrive to the emergency department in cardiac arrest also have higher survival rates (12 to 19 percent) compared with those without vital signs (0 to 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/53-55,59\">",
"     53-55,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One retrospective review of 102 patients undergoing thoracotomy over a 25-year period identified an overall survival rate of 7.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/53\">",
"     53",
"    </a>",
"    ]. The patient population was stratified by the Lorenz Physiologic Status Classification based upon vital signs and signs of life as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I - No signs of life",
"     </li>",
"     <li>",
"      Class II - Agonal (ie, pulseless electrical activity, no blood pressure)",
"     </li>",
"     <li>",
"      Class III - profound shock (ie, BP &lt;60 mmHg)",
"     </li>",
"     <li>",
"      Class IV - Mild shock (ie, 60 &lt;BP &lt;90 mmHg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Survival rates improved significantly with higher physiologic status. Survival was 0.7 percent in Class I patients improving to 44.4 percent in class IV patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for cardiopulmonary resuscitation (CPR) in the field is also associated with low survival rates. Although CPR in the field portends a poor prognosis, CPR in the presence of cardiac tamponade has a more favorable outcome, particularly among patients with stab wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/57\">",
"     57",
"    </a>",
"    ]. For patients with blunt trauma, CPR in the field is associated with no meaningful survival; any survivors are not likely to be neurologically intact [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/47,57\">",
"     47,57",
"    </a>",
"    ]. For patients with penetrating injuries, survival is possible if the total time for CPR in the field is brief (&lt;5 minutes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108031298\">",
"    <span class=\"h2\">",
"     Neurologic outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitative thoracotomy as a means to salvage patients in extremis has the unintended consequence of saving a group of patients who then suffer from anoxic brain injury and have severe permanent neurologic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/9,19,47,48,50,56,66\">",
"     9,19,47,48,50,56,66",
"    </a>",
"    ]. In the systematic review discussed above, 7 percent of the patients who survived were neurologically impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/19\">",
"     19",
"    </a>",
"    ]. A later database review from the Western Trauma Association reported that 18 percent of survivors had moderate to severe neurologic deficits requiring long-term care placement [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/48\">",
"     48",
"    </a>",
"    ]. Other series have reported an incidence of permanent neurologic deficits between these values, but some studies have reported higher rates. In a study that looked at the clinical condition of the patient upon arrival, neurologically intact survival following resuscitative thoracotomy occurred in fewer than 5 percent of those who arrived to the emergency department in shock, was 1 percent for those without vital signs, and 0 percent for those without signs of life in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108020054\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitative thoracotomy is expensive in terms of human resources, use of blood products, and potential consequences of the blood exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/47,58,67-70\">",
"     47,58,67-70",
"    </a>",
"    ]. Costs associated with other aspects of resuscitative thoracotomy include expenditures related to community emergency medical services, hospital resources including supplies, personnel and transfusion services, and consequences of blood-borne pathogen exposures. Finally, the long-term care of the patient with permanent neurologic impairment also needs to be taken into account.",
"   </p>",
"   <p>",
"    Using survival and neurologic impairment data, rates and costs of occupational exposure from published studies, a cost utility analysis calculated the incremental cost-effectiveness ratio of resuscitative thoracotomy for penetrating and blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31801/abstract/71\">",
"     71",
"    </a>",
"    ]. Resuscitative thoracotomy for penetrating trauma was found to be cost-effective at $16,125 per quality-adjusted life year (QALY). The probability of a QALY of less than $50,000 per QALY was 93 percent for penetrating trauma. In contrast, the incremental cost-effectiveness ratio for blunt trauma was $163,136 per QALY, with a probability of only 37 percent for QALY less than $50,000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1247118679\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resuscitative thoracotomy is a procedure of last resort in the management of patients with major trauma. It is performed in patients with penetrating or blunt thoracic or exsanguinating abdominal injury who are in extremis, but only under specific clinical circumstances,",
"      <strong>",
"       and",
"      </strong>",
"      only if appropriate resources are available for definitive injury management. (See",
"      <a class=\"local\" href=\"#H1247118515\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H197313272\">",
"       'Indications for thoracotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the decision has been made to open the chest, one member of the trauma team should be designated to lead the ongoing resuscitation effort while the senior member of the trauma team is performing the thoracotomy. Given the potential for blood splatter and the prevalence of blood-borne disease in the trauma population, all personnel involved in the care of the trauma patient should observe universal precautions wearing gowns, gloves, and eye protection at all times. (See",
"      <a class=\"local\" href=\"#H1247118578\">",
"       'Preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resuscitative thoracotomy is performed through an anterolateral incision in the 4",
"      <sup>",
"       th",
"      </sup>",
"      or 5",
"      <sup>",
"       th",
"      </sup>",
"      intercostal space in a systematic manner. Given the indications for resuscitative thoracotomy (ie, patient in extremis with loss of vital signs), the steps are generally performed in a defined order; however, the clinical presentation of the patient or the nature of specific injuries may make one step take precedence over another. The typical approach is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The incision is made, the chest is entered, and a retractor is placed. (See",
"      <a class=\"local\" href=\"#H108020288\">",
"       'Incision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108022140\">",
"       'Opening the chest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Damage control maneuvers are used to manage hemorrhage that will impede performance of pericardiotomy or aortic cross-clamping. (See",
"      <a class=\"local\" href=\"#H108028383\">",
"       'Damage control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pericardial sac is opened and evacuated of any blood or clots, and temporizing measures are used to control cardiac injuries, if present. Signs of air embolism are identified and treated. (See",
"      <a class=\"local\" href=\"#H108022308\">",
"       'Pericardiotomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1247118637\">",
"       'Hemorrhage control and repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1247118651\">",
"       'Identifying and evacuating air embolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aorta is cross-clamped, which facilitates filling of the heart and ongoing fluid resuscitation. (See",
"      <a class=\"local\" href=\"#H1247118616\">",
"       'Aortic cross-clamping'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open cardiac massage is initiated once the heart has filled sufficiently. (See",
"      <a class=\"local\" href=\"#H1247118630\">",
"       'Open cardiac massage and internal defibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The thoracic structures are systematically explored, looking for any active bleeding or hematoma formation that might suggest underlying injury. (See",
"      <a class=\"local\" href=\"#H1247118637\">",
"       'Hemorrhage control and repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient regains vital signs, he or she is transferred to the operating room for definitive management of the identified injuries by a multidisciplinary trauma team. (See",
"      <a class=\"local\" href=\"#H108028522\">",
"       'Definitive management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival following resuscitative thoracotomy is consistently better in patients with penetrating thoracic injury compared with those who have blunt injury. Survival also depends upon the clinical status of the patient prior to arrival in the emergency department, approaching zero percent for those who do not have signs of life or vital signs in the field. Of those who survive, permanent neurologic deficits occur in 7 to 18 percent of patients. (See",
"      <a class=\"local\" href=\"#H536270528\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/1\">",
"      Beall AC Jr, Diethrich EB, Crawford HW, et al. Surgical management of penetrating cardiac injuries. Am J Surg 1966; 112:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/2\">",
"      Seamon MJ, Shiroff AM, Franco M, et al. Emergency department thoracotomy for penetrating injuries of the heart and great vessels: an appraisal of 283 consecutive cases from two urban trauma centers. J Trauma 2009; 67:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/3\">",
"      Wiencek RG Jr, Wilson RF. Injuries to the abdominal vascular system: how much does aggressive resuscitation and prelaparotomy thoracotomy really help? Surgery 1987; 102:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/4\">",
"      Seamon MJ, Pathak AS, Bradley KM, et al. Emergency department thoracotomy: still useful after abdominal exsanguination? J Trauma 2008; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/5\">",
"      Ledgerwood AM, Kazmers M, Lucas CE. The role of thoracic aortic occlusion for massive hemoperitoneum. J Trauma 1976; 16:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/6\">",
"      Sankaran S, Lucas C, Walt AJ. Thoracic aortic clamping for prophylaxis against sudden cardiac arrest during laparotomy for acute massive hemoperitoneum. J Trauma 1975; 15:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/7\">",
"      Natsis KI, Tsitouridis IA, Didagelos MV, et al. Anatomical variations in the branches of the human aortic arch in 633 angiographies: clinical significance and literature review. Surg Radiol Anat 2009; 31:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/8\">",
"      Demetriades D. An unusual anatomical aortic arch variation. J Trauma 2005; 58:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/9\">",
"      Seamon MJ, Chovanes J, Fox N, et al. The use of emergency department thoracotomy for traumatic cardiopulmonary arrest. Injury 2012; 43:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/10\">",
"      Henein MN, Lloyd L. HIV, hepatitis B, and hepatitis C in the Code One trauma population. Am Surg 1997; 63:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/11\">",
"      Kaplan AJ, Zone-Smith LK, Hannegan C, Norcross ED. The prevalence of hepatitis C in a regional level I trauma center population. J Trauma 1992; 33:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/12\">",
"      Seamon MJ, Ginwalla R, Kulp H, et al. HIV and hepatitis in an urban penetrating trauma population: unrecognized and untreated. J Trauma 2011; 71:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/13\">",
"      Xeroulis G, Inaba K, Stewart TC, et al. Human immunodeficiency virus, hepatitis B, and hepatitis C seroprevalence in a Canadian trauma population. J Trauma 2005; 59:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/14\">",
"      Caplan ES, Preas MA, Kerns T, et al. Seroprevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and rapid plasma reagin in a trauma population. J Trauma 1995; 39:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/15\">",
"      Orr MD, Hoos A, Riester DE, et al. Surveillance for HIV antibody and antigen in trauma patients. J Emerg Med 1991; 9 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/16\">",
"      Rudolph R, Bowen DG, Boyd CR, Jurgensen P. Seroprevalence of human immunodeficiency virus in admitted trauma patients at a southeastern metropolitan/rural trauma center. Am Surg 1993; 59:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/17\">",
"      Sloan EP, McGill BA, Zalenski R, et al. Human immunodeficiency virus and hepatitis B virus seroprevalence in an urban trauma population. J Trauma 1995; 38:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/18\">",
"      Charache P, Cameron JL, Maters AW, Frantz EI. Prevalence of infection with human immunodeficiency virus in elective surgery patients. Ann Surg 1991; 214:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/19\">",
"      Rhee PM, Acosta J, Bridgeman A, et al. Survival after emergency department thoracotomy: review of published data from the past 25 years. J Am Coll Surg 2000; 190:288.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. HIV surveillance report, vol. 20. 2008.",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Surveillance for acute viral hepati-tis&mdash;United States, 2007. Morbidity and Mortality Weekly Report 2009;58(SS3): 1&ndash;32.",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Updated U.S. public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. Morbidity and Mortality Weekly Report 2001;50(RR11):1&ndash;42.",
"    </li>",
"    <li>",
"     Johnson, JL, Moore, EE. Thoracic Trauma. In: Master of Surgery, 5th Ed, Bland, KI, Fischer, JE.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. Vol 1, p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/24\">",
"      Sobnach S, Nicol A, Nathire H, et al. Management of the retained knife blade. World J Surg 2010; 34:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/25\">",
"      Wilson A, Wall MJ Jr, Maxson R, Mattox K. The pulmonary hilum twist as a thoracic damage control procedure. Am J Surg 2003; 186:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/26\">",
"      Powell RJ, Redan JA, Swan KG. The hilar snare, and improved technique for securing rapid vascular control of the pulmonary hilum. J Trauma 1990; 30:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/27\">",
"      Baumgartner F, Omari B, Lee J, et al. Survival after trauma pneumonectomy: the pathophysiologic balance of shock resuscitation with right heart failure. Am Surg 1996; 62:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/28\">",
"      Cryer HG, Mavroudis C, Yu J, et al. Shock, transfusion, and pneumonectomy. Death is due to right heart failure and increased pulmonary vascular resistance. Ann Surg 1990; 212:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/29\">",
"      Kralovich KA, Morris DC, Dereczyk BE, et al. Hemodynamic effects of aortic occlusion during hemorrhagic shock and cardiac arrest. J Trauma 1997; 42:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/30\">",
"      Dunn EL, Moore EE, Moore JB. Hemodynamic effects of aortic occlusion during hemorrhagic shock. Ann Emerg Med 1982; 11:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/31\">",
"      Millikan JS, Moore EE. Outcome of resuscitative thoracotomy and descending aortic occlusion performed in the operating room. J Trauma 1984; 24:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/32\">",
"      Spence PA, Lust RM, Chitwood WR Jr, et al. Transfemoral balloon aortic occlusion during open cardiopulmonary resuscitation improves myocardial and cerebral blood flow. J Surg Res 1990; 49:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/33\">",
"      Wesley RC Jr, Morgan DB. Effect of continuous intra-aortic balloon inflation in canine open chest cardiopulmonary resuscitation. Crit Care Med 1990; 18:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/34\">",
"      DeBehnke DJ, Angelos MG, Leasure JE. Comparison of standard external CPR, open-chest CPR, and cardiopulmonary bypass in a canine myocardial infarct model. Ann Emerg Med 1991; 20:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/35\">",
"      Luna GK, Pavlin EG, Kirkman T, et al. Hemodynamic effects of external cardiac massage in trauma shock. J Trauma 1989; 29:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/36\">",
"      Rubertsson S, Grenvik A, Wiklund L. Blood flow and perfusion pressure during open-chest versus closed-chest cardiopulmonary resuscitation in pigs. Crit Care Med 1995; 23:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/37\">",
"      Bircher N, Safar P. Manual open-chest cardiopulmonary resuscitation. Ann Emerg Med 1984; 13:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/38\">",
"      Mattox KL, Feliciano DV. Role of external cardiac compression in truncal trauma. J Trauma 1982; 22:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/39\">",
"      Boczar ME, Howard MA, Rivers EP, et al. A technique revisited: hemodynamic comparison of closed- and open-chest cardiac massage during human cardiopulmonary resuscitation. Crit Care Med 1995; 23:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/40\">",
"      Kang N, Hsee L, Rizoli S, Alison P. Penetrating cardiac injury: overcoming the limits set by Nature. Injury 2009; 40:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/41\">",
"      Asensio JA, Murray J, Demetriades D, et al. Penetrating cardiac injuries: a prospective study of variables predicting outcomes. J Am Coll Surg 1998; 186:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/42\">",
"      Shaikh N, Ummunisa F. Acute management of vascular air embolism. J Emerg Trauma Shock 2009; 2:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/43\">",
"      LeDez KM. Air embolism and blunt chest trauma. Can J Anaesth 2011; 58:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/44\">",
"      Ka��dash AN. [A method of removing air from the cavities of the heart and great vessels during surgery with extracorporeal circulation]. Grud Serdechnososudistaia Khir 1991; :31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/45\">",
"      Lang JL, Gonzalez RP, Aldy KN, et al. Does temporary chest wall closure with or without chest packing improve survival for trauma patients in shock after emergent thoracotomy? J Trauma 2011; 70:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/46\">",
"      Vargo DJ, Battistella FD. Abbreviated thoracotomy and temporary chest closure: an application of damage control after thoracic trauma. Arch Surg 2001; 136:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/47\">",
"      Powell DW, Moore EE, Cothren CC, et al. Is emergency department resuscitative thoracotomy futile care for the critically injured patient requiring prehospital cardiopulmonary resuscitation? J Am Coll Surg 2004; 199:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/48\">",
"      Moore EE, Knudson MM, Burlew CC, et al. Defining the limits of resuscitative emergency department thoracotomy: a contemporary Western Trauma Association perspective. J Trauma 2011; 70:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/49\">",
"      Pahle AS, Pedersen BL, Skaga NO, Pillgram-Larsen J. Emergency thoracotomy saves lives in a Scandinavian hospital setting. J Trauma 2010; 68:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/50\">",
"      Karmy-Jones R, Nathens A, Jurkovich GJ, et al. Urgent and emergent thoracotomy for penetrating chest trauma. J Trauma 2004; 56:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/51\">",
"      Siram S, Oyetunji T, Johnson SM, et al. Predictors for survival of penetrating trauma using emergency department thoracotomy in an urban trauma center: the Cardiac Instability Score. J Natl Med Assoc 2010; 102:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/52\">",
"      Seamon MJ, Fisher CA, Gaughan JP, et al. Emergency department thoracotomy: survival of the least expected. World J Surg 2008; 32:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/53\">",
"      Gomez G, Fecher A, Joy T, et al. Optimizing outcomes in emergency room thoracotomy: a 20-year experience in an urban Level I trauma center. Am Surg 2010; 76:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/54\">",
"      Moriwaki Y, Sugiyama M, Toyoda H, et al. Cardiopulmonary arrest on arrival due to penetrating trauma. Ann R Coll Surg Engl 2010; 92:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/55\">",
"      Cothren CC, Moore EE. Emergency department thoracotomy for the critically injured patient: Objectives, indications, and outcomes. World J Emerg Surg 2006; 1:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/56\">",
"      Lockey D, Crewdson K, Davies G. Traumatic cardiac arrest: who are the survivors? Ann Emerg Med 2006; 48:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/57\">",
"      Branney SW, Moore EE, Feldhaus KM, Wolfe RE. Critical analysis of two decades of experience with postinjury emergency department thoracotomy in a regional trauma center. J Trauma 1998; 45:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/58\">",
"      Esposito TJ, Jurkovich GJ, Rice CL, et al. Reappraisal of emergency room thoracotomy in a changing environment. J Trauma 1991; 31:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/59\">",
"      Boyd M, Vanek VW, Bourguet CC. Emergency room resuscitative thoracotomy: when is it indicated? J Trauma 1992; 33:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/60\">",
"      Fialka C, Seb&ouml;k C, Kemetzhofer P, et al. Open-chest cardiopulmonary resuscitation after cardiac arrest in cases of blunt chest or abdominal trauma: a consecutive series of 38 cases. J Trauma 2004; 57:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/61\">",
"      Durham LA 3rd, Richardson RJ, Wall MJ Jr, et al. Emergency center thoracotomy: impact of prehospital resuscitation. J Trauma 1992; 32:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/62\">",
"      Demirhan R, Onan B, Oz K, Halezeroglu S. Comprehensive analysis of 4205 patients with chest trauma: a 10-year experience. Interact Cardiovasc Thorac Surg 2009; 9:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/63\">",
"      Onat S, Ulku R, Avci A, et al. Urgent thoracotomy for penetrating chest trauma: analysis of 158 patients of a single center. Injury 2010; 41:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/64\">",
"      Millham FH, Grindlinger GA. Survival determinants in patients undergoing emergency room thoracotomy for penetrating chest injury. J Trauma 1993; 34:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/65\">",
"      Lorenz HP, Steinmetz B, Lieberman J, et al. Emergency thoracotomy: survival correlates with physiologic status. J Trauma 1992; 32:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/66\">",
"      Baker CC, Caronna JJ, Trunkey DD. Neurologic outcome after emergency room thoracotomy for trauma. Am J Surg 1980; 139:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/67\">",
"      Mazzorana V, Smith RS, Morabito DJ, Brar HS. Limited utility of emergency department thoracotomy. Am Surg 1994; 60:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/68\">",
"      Pasquale MD, Rhodes M, Cipolle MD, et al. Defining \"dead on arrival\": impact on a level I trauma center. J Trauma 1996; 41:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/69\">",
"      Rosemurgy AS, Norris PA, Olson SM, et al. Prehospital traumatic cardiac arrest: the cost of futility. J Trauma 1993; 35:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/70\">",
"      Velmahos GC, Degiannis E, Souter I, et al. Outcome of a strict policy on emergency department thoracotomies. Arch Surg 1995; 130:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31801/abstract/71\">",
"      Brown TB, Romanello M, Kilgore M. Cost-utility analysis of emergency department thoracotomy for trauma victims. J Trauma 2007; 62:1180.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15153 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31801=[""].join("\n");
var outline_f31_3_31801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1247118679\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118515\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197313272\">",
"      INDICATIONS FOR THORACOTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24289990\">",
"      Penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H197314164\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24290008\">",
"      Blunt injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24290614\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118564\">",
"      THORACIC ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118578\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24289882\">",
"      Equipment and supplies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4649316\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4649357\">",
"      Universal precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H536270443\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108024991\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108020288\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108022140\">",
"      Opening the chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108028383\">",
"      Damage control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108022308\">",
"      Pericardiotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118616\">",
"      Aortic cross-clamping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118630\">",
"      Open cardiac massage and internal defibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118637\">",
"      Hemorrhage control and repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118651\">",
"      Identifying and evacuating air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108028522\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H536270528\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108031298\">",
"      Neurologic outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108020054\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1247118679\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15153|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/36/39489\" title=\"algorithm 1\">",
"      Blunt chest trauma in adults algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15153|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/38/24168\" title=\"figure 1\">",
"      Normal thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/47/5878\" title=\"figure 2\">",
"      Variations of aortic arch branching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/21/16725\" title=\"figure 3\">",
"      Left phrenic nerve course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/12/8389\" title=\"figure 4\">",
"      Anterolateral thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/32/24069\" title=\"figure 5\">",
"      Intercostal space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/12/5320\" title=\"figure 6\">",
"      Control of the lung hilum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/31/43505\" title=\"figure 7\">",
"      Pericardiotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/41/13970\" title=\"figure 8\">",
"      Cross-clamping the thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/62/38895\" title=\"figure 9\">",
"      Open cardiac massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/9/24722\" title=\"figure 10\">",
"      Repair of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15153|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/16/22789\" title=\"picture 1\">",
"      Emergency thoracotomy pericardiotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/53/9047\" title=\"picture 2\">",
"      Emergency thoracotomy aortic cross clamp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15153|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/22/34155\" title=\"table 1\">",
"      Instruments for emergency thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/48/27404\" title=\"table 2\">",
"      Antimicrobial prophylaxis for thoracic non-cardiac surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=related_link\">",
"      Initial evaluation and management of abdominal stab wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=related_link\">",
"      Operating room safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=related_link\">",
"      Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31802="Initial treatment of moderately to severely active rheumatoid arthritis in adults";
var content_f31_3_31802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31802/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31802/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31802/contributors\">",
"     Stanley Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31802/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31802/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/3/31802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/3/31802/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/3/31802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3692501\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of rheumatoid arthritis (RA) is directed toward the control of synovitis and the prevention of joint injury. Support for an early aggressive approach to treatment is based upon the observations that joint damage, which may ultimately result in disability, begins early in the course of disease and that, the longer active disease persists, the less likely the patient is to respond to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/1\">",
"     1",
"    </a>",
"    ]. Improved outcomes have resulted from the use of potent and well-tolerated nonbiologic (traditional) and biologic disease-modifying antirheumatic drugs (DMARDs) used alone and in combination to induce and maintain tight control of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. These medications and strategies have the potential to control synovitis and to slow or stop radiographic progression [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/2,9,11,12\">",
"     2,9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations regarding the course of disease and the efficacy of current therapeutic approaches, coupled with limits in the ability to accurately identify individuals with a poor prognosis, support our view that every patient with established active RA should be treated with DMARDs at the earliest stage of disease, ideally within three months of symptom onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of patients with moderately to severely active RA, regardless of duration, will be reviewed here. The diagnosis and differential diagnosis, the general principles of management, an overview of the therapy of RA, the initial treatment of mildly active RA, and the treatment of disease resistant to initial therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF MODERATELY TO SEVERELY ACTIVE RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderately to severely active RA are at greater risk of developing joint damage and disability than patients with mildly active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/13\">",
"     13",
"    </a>",
"    ]. These patients typically meet the American College of Rheumatology",
"    <span class=\"nowrap\">",
"     (ACR)/European",
"    </span>",
"    League Against Rheumatism (EULAR) criteria for RA and exhibit a combination of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least five inflamed joints",
"     </li>",
"     <li>",
"      Elevation in the erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum C-reactive protein (CRP) concentration",
"     </li>",
"     <li>",
"      Positive rheumatoid factor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anticyclic citrullinated peptide (CCP) antibodies (present in most patients)",
"     </li>",
"     <li>",
"      Evidence of inflammation on plain radiography of the hands, wrists, or feet, such as osteopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      periarticular swelling. In addition, minimal joint space narrowing and small peripheral erosions may be observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and differential diagnosis of RA, as well as RA classification criteria, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3692872\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several general principles important in the management of all patients with RA. These principles are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, these include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Achievement and maintenance of tight control of disease activity, defined as remission or a state of minimal disease activity, without compromising safety",
"     </li>",
"     <li>",
"      Treatment of all patients diagnosed with RA with disease-modifying antirheumatic drug (DMARD) therapy",
"     </li>",
"     <li>",
"      Use of antiinflammatory therapies, including nonsteroidal antiinflammatory drugs and glucocorticoids, to help control symptoms until DMARDs take effect",
"     </li>",
"     <li>",
"      Evaluation and ongoing care by a rheumatologist",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2985885\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonpharmacologic measures and other medical interventions are important in the comprehensive management of RA, in addition to antiinflammatory and antirheumatic drug therapies. These interventions, including patient education, vaccinations, and others, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     APPROACH TO DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to therapy is based upon the widely favored view that all patients diagnosed with RA should receive DMARDs to prevent, arrest, or retard disease-related injury, as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Recommendations of major groups support the early use of disease-modifying antirheumatic drugs (DMARDs), usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), for most patients with active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In some patients with mild disease, particularly those with minimal or low levels of disease activity, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , as described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is our general approach to the selection of drug therapies for the initial therapy of patients with moderately to severely active RA. It is broadly consistent with the 2008 and 2012 American College of Rheumatology recommendations and with the 2010 recommendations of the European League Against Rheumatism [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We initiate therapy with a DMARD or combinations of DMARDs. We suggest MTX as the initial DMARD. (See",
"      <a class=\"local\" href=\"#H3981583\">",
"       'Initial therapy with methotrexate'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients unable to take MTX, we use monotherapy with a TNF inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3982784\">",
"       'Alternatives to MTX'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3982842\">",
"       'TNF inhibitors'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3982900\">",
"       'Nonbiologic DMARD alternatives to MTX'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We add nonsteroidal antiinflammatory drugs (NSAIDs)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glucocorticoids (systemic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intraarticular) for initial symptomatic control of inflammation, while awaiting the response to DMARD therapy. We do not use these NSAIDs or glucocorticoids as the sole or primary treatments. (See",
"      <a class=\"local\" href=\"#H3693478\">",
"       'NSAIDs'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3693989\">",
"       'Glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the response to appropriate doses of MTX monotherapy is inadequate after three to six months or if there are persistently high levels of disease activity on MTX alone, our preferred approach is to initiate combination therapy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Monitoring and reevaluation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"       \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3981569\">",
"    <span class=\"h1\">",
"     DMARD THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We initially use one of the more effective disease modifying antirheumatic drugs (DMARDs), usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , both to suppress synovitis and other signs and symptoms of active disease and to prevent articular bone erosions and joint space narrowing. We initiate DMARD therapy early in the treatment of RA because delayed use of such medications results in poorer physical function and in increased joint injury [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous meta-analyses and randomized, controlled trials support the use of nonbiologic (traditional) and biologic DMARDs in patients with active RA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14,21-29\">",
"     14,21-29",
"    </a>",
"    ]. These trials included a mix of patients with moderate and severely active disease and a mean duration of illness of 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/3,6,18,28-31\">",
"     3,6,18,28-31",
"    </a>",
"    ]. The applicability of these studies to the initial treatment of patients with active disease is addressed together with the other evidence described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3981576\">",
"    <span class=\"h2\">",
"     Pretreatment interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;We take a number of important precautions before using DMARDs, including laboratory assessment (complete blood count, serum creatinine, aminotransferases, and other studies as indicated), evaluation of comorbidities, vaccinations, and screening for hepatitis C, hepatitis B, and latent tuberculosis infection. A chest radiograph should be obtained prior to initiating treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link&amp;anchor=H11#H11\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\", section on 'Vaccinations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link&amp;anchor=H3#H3\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Pulmonary toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3981583\">",
"    <span class=\"h2\">",
"     Initial therapy with methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) as the DMARD of choice for the initial treatment of patients with moderately to severely active RA. MTX typically serves as the &ldquo;anchor&rdquo; drug for the most commonly used DMARD combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The major issues regarding the use of MTX in RA will be briefly reviewed here but are discussed in further detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Dosing of MTX'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/457?source=see_link&amp;anchor=H3760730#H3760730\">",
"     \"Effects of antiinflammatory and immunosuppressive drugs on gonadal function in men with rheumatic diseases\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MTX is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in several groups of patients. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Women who are contemplating becoming pregnant",
"     </li>",
"     <li>",
"      Women who are pregnant",
"     </li>",
"     <li>",
"      Patients with liver disease or excessive alcohol intake",
"     </li>",
"     <li>",
"      Patients with severe renal impairment (estimated glomerular filtration rate less than 30",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Male partners of women contemplating becoming pregnant should exercise caution regarding the use of MTX for three months prior to conception, if possible, given the very limited data regarding evidence of risk in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/457?source=see_link&amp;anchor=H3760730#H3760730\">",
"     \"Effects of antiinflammatory and immunosuppressive drugs on gonadal function in men with rheumatic diseases\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982770\">",
"    <span class=\"h3\">",
"     MTX dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is given in a",
"    <strong>",
"     single weekly",
"    </strong>",
"    dose, usually orally. The optimal starting dose and schedule for dose escalation are uncertain. We suggest initiating therapy at a dose between 7.5 and 15 mg once weekly for most patients, depending upon the degree of disease activity, the size and age of the patient, the presence of comorbidities, and renal function. As examples, we would treat a 70-year-old patient weighing 55 kg with moderately active disease with an initial dose of 7.5 mg once weekly, while an otherwise healthy 30-year-old patient weighing 80 kg with highly active disease would be started on 15 mg once weekly. A lower initial dose is essential in patients with reduced renal function, defined as an estimated glomerular filtration rate (eGFR) &lt;60",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Dosing of MTX'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H10#H10\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The MTX dose is increased as tolerated and as needed to control symptoms and signs of arthritis. Our usual approach is to increase the dose after four weeks at a rate of 2.5 mg (one tablet) per week as indicated by disease activity and as tolerated. In patients with continued high disease activity, we may increase by up to 5",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    if few comorbidities are present and if the increase in the dose continues to be well-tolerated. The usual target dose is at least 15",
"    <span class=\"nowrap\">",
"     mg/week;",
"    </span>",
"    the usual maximum dose is 25",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    Alternative dose titration strategies may also be employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H10#H10\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In early RA trials in which the dose of MTX is rapidly increased to 20",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    and in which the drug is continued for at least three months, approximately 30 percent of patients achieve a DAS28 less than or equal to 3.2, consistent with low disease activity, within three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients in whom 20 to 25 mg of MTX orally once weekly is ineffective or is poorly tolerated because of gastrointestinal symptoms, a trial of subcutaneous MTX administration is an alternative to switching to another DMARD or to adding a TNF inhibitor. Alternatively, MTX is better absorbed, particularly at doses of 15",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    or greater, if the dose is split into two doses on the day of administration. It is imperative to tell the patient to take all the MTX over a single 24-hour period once a week, as spreading the dose out further may produce significant liver toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H11#H11\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Split dosing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Parenteral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Pharmacology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3984111\">",
"    <span class=\"h3\">",
"     Side effects, monitoring, and other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX treatment requires meticulous monitoring for bone marrow, liver, and lung toxicity. The toxicities associated with MTX in the doses used in RA are very rarely life-threatening in patients receiving recommended monitoring. MTX is generally well-tolerated, although most patients experience at least one or more of the more common side effects, such as gastrointestinal upset or stomatitis, over their course of therapy. MTX is discontinued due to adverse effects after two and five years of treatment in up to 20 and 35 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/23\">",
"     23",
"    </a>",
"    ]. The major side effects of low-dose MTX are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients receiving MTX should also receive daily supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . The use of folic acid and additional considerations with the use of MTX that are discussed in more detail separately include alcohol ingestion and dosing in renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207103444\">",
"    <span class=\"h3\">",
"     MTX versus other DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized head-to-head trials have found that MTX has a faster onset of action, comparable or greater efficacy, and better long-term tolerance, compared with other nonbiologic DMARD monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/23\">",
"     23",
"    </a>",
"    ]. MTX has also been shown to improve survival (both cardiovascular and all-cause mortality) in patients with RA compared with other nonbiologic DMARDs [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/37\">",
"     37",
"    </a>",
"    ]. However, practically all trials that originally led to the widespread use of MTX in this role were performed in patients with well-established RA, often after several years of disease, rather than soon after the initial development of inflammatory arthritis. In addition, these trials used lower doses than are typically used at present. Despite this, we feel that these relative benefits with MTX extend to those with early active RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H5#H5\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Efficacy for arthritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Possible survival benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In randomized trials, initial therapy with MTX results in comparable benefit to initial therapy with a TNF inhibitor alone [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Approaches using tight control treatment strategies have shown significant benefit without the use of biologics for initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H6422708#H6422708\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Tight control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207103451\">",
"    <span class=\"h3\">",
"     MTX versus initial combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of MTX with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ), with both SSZ and HCQ, or with a biologic DMARD also have proven efficacy for initial treatment of highly active RA in patients with poor prognostic features [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14,39\">",
"     14,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=see_link\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link&amp;anchor=H109283721#H109283721\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\", section on 'Approach to drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, we prefer MTX monotherapy for initial treatment rather than in combination with other nonbiologic or biologic DMARDs or a biologic DMARD alone, despite the fact that a greater proportion of patients respond well when treated initially with combination therapies or biologics [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/39\">",
"     39",
"    </a>",
"    ]. This is principally because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial MTX monotherapy is adequate in many patients with early, moderately to severely active RA; those with an inadequate response can be quickly identified and subsequently treated with combination therapy prior to the development of irreversible injury [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/28,29,35,38,40,41\">",
"       28,29,35,38,40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical outcomes after several years of treatment are similar in trials that compared patients initially receiving MTX, who then stepped up to combination therapy after an inadequate response, with patients initially treated with combination therapy. Long-term clinical outcomes between such groups are not well-studied. However, radiographic differences at two years in such trials, while favoring the initial combination groups, have been very small, and their clinical significance remains to be determined [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/4,35,42,43\">",
"       4,35,42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with MTX, there is less information available regarding the long-term safety of biologic DMARDs, and there is some evidence that the risk may be greater with these agents. There are also widespread regulatory or cost barriers to the use of biologic therapies for initial DMARD treatment for most DMARD-naive patients, even with severely active RA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982784\">",
"    <span class=\"h2\">",
"     Alternatives to MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data to identify the optimal initial therapy in patients with moderately to severely active RA who are unable to take MTX. The choice of agent is largely based upon indirect comparisons, limited head-to-head comparisons, regulatory or insurance requirements, and patient preferences regarding relative risks and benefits, route of administration, and cost.",
"   </p>",
"   <p>",
"    The principal options are a tumor necrosis factor (TNF) inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    (LEF), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are not restricted by regulatory or cost constraints, we suggest the use of a TNF inhibitor. Among the available agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      is our first choice, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In patients who prefer an orally administered or less costly agent, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3982900\">",
"       'Nonbiologic DMARD alternatives to MTX'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from randomized trials demonstrating the benefit of each agent compared with placebo, as well as head-to-head comparisons of MTX with TNF inhibitors and of MTX, LEF, and SSZ with each other, are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link&amp;anchor=H16#H16\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\", section on 'Use in RA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link&amp;anchor=H17#H17\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\", section on 'Comparison with MTX'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link&amp;anchor=H18#H18\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\", section on 'Comparison with sulfasalazine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link&amp;anchor=H16#H16\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Patients with mild activity and poor prognostic signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982842\">",
"    <span class=\"h3\">",
"     TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of biologic DMARDs, particularly the tumor necrosis factor (TNF)-alpha inhibitors, have been proven effective as monotherapy, compared with placebo or MTX, in randomized trials in patients with moderately and severely active RA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/28,29,39\">",
"     28,29,39",
"    </a>",
"    ]. Although the biologic DMARDs have not been directly compared with each other, indirect analyses are available [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the patient who is unable to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), we use either of the following TNF inhibitors for initial therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; Etanercept has shown generally similar or modestly greater efficacy compared with MTX in randomized trials. There is slightly longer experience with this agent, and there is indirect evidence of lower rates of serious infections compared with other biologic DMARDs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. In our experience, benefit is also reached more quickly with etanercept and other TNF inhibitors than with most nonbiologic DMARDs, including MTX,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      . The data demonstrating the efficacy of etanercept are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link&amp;anchor=H3#H3\">",
"       \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Etanercept'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      &mdash; Adalimumab is also effective in this group of patients; it can be administered as an every other week injection, which some patients prefer to a weekly injection [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. The use of adalimumab is supported by randomized trials showing comparable efficacy to MTX as initial DMARD monotherapy and by indirect comparisons in a meta-analysis of randomized trials showing comparable efficacy to other TNF inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/27,29\">",
"       27,29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link&amp;anchor=H5#H5\">",
"       \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Adalimumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The newer TNF inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , are also effective as monotherapy, but there is less long-term experience with these newer medications. As a result, we generally prefer other alternatives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link&amp;anchor=H7#H7\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Certolizumab pegol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link&amp;anchor=H6#H6\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Golimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    alone is generally NOT recommended due to the increased likelihood of developing inactivating human antichimeric antibodies (HACA) when this chimeric monoclonal antibody is given without other immunosuppressive drugs. However, we recognize that, in clinical practice, some patients receive infliximab alone. Loss of efficacy due to emergence of HACA may be overcome by use of increasing doses or by increased frequency of administration of infliximab, although the increased cost associated with this approach may be prohibitive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=see_link&amp;anchor=H5#H5\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\", section on 'Human antichimeric antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects of TNF inhibitors are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rates of toxicity requiring drug withdrawal in practice are not well-established. In one study of a cohort of 6739 patients with RA receiving new treatment with a TNF inhibitor, 15 percent of patients stopped their drug due to toxicity after a mean follow-up of 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/44\">",
"     44",
"    </a>",
"    ]. Results from patients in randomized trials are even lower but are difficult to generalize to patients being seen in practice or receiving treatment for more than one or two years [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982900\">",
"    <span class=\"h3\">",
"     Nonbiologic DMARD alternatives to MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients unable to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), effective nonbiologic alternatives for initial therapy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    (LEF) and, in some patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      &mdash; We use leflunomide (LEF) in patients who, for regulatory, insurance, or cost reasons, are unable to use MTX or a biologic DMARD for initial treatment. We may also use LEF in patients who have a strong preference for an oral rather than a parenteral agent.",
"      <br/>",
"      <br/>",
"      The efficacy of LEF was comparable to MTX and superior to placebo in a meta-analysis and in randomized trials comparing these agents, but these trials have been criticized for using lower maximum doses of MTX (up to 15",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      than have subsequently been commonly employed (up to 25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. LEF has not been directly compared with the TNF inhibitors, but the superiority of TNF inhibitors is suggested by the comparability of LEF to sometimes suboptimal doses of MTX and to SSZ; by the more rapid effects and greater overall benefit of TNF inhibitors when they have been directly compared with MTX or SSZ; and by clinical experience. The supporting data are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"       \"Leflunomide in the treatment of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link\">",
"       \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Among nonbiologic DMARDs, we prefer LEF over SSZ because of its possible greater effectiveness for the treatment of severely active RA, regardless of the presence or absence of poor prognostic factors [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14,24,25\">",
"       14,24,25",
"      </a>",
"      ]. Some randomized trials suggest that LEF is more effective than SSZ in achieving a clinical response, in decreasing functional disability, and in reducing progression of erosive changes [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]; others indicate comparable efficacy of the two agents [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Additionally, the adverse effect profile of LEF is generally similar to that of MTX, with similar rates of withdrawal for drug toxicity at two years [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/52,54\">",
"       52,54",
"      </a>",
"      ]. The drug should be used with caution in patients with renal insufficiency. The data that support the efficacy of LEF in the treatment of RA are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"       \"Leflunomide in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      &mdash; We limit the use of sulfasalazine (SSZ) as an alternative to MTX to patients who do not have any poor prognostic features, who have a strong preference for an oral agent, and in whom LEF is contraindicated. SSZ alone (begun at 500 mg twice daily and gradually increased [eg, by 500 mg per week] to up to 1000 mg two or three times daily) or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      can be effective as the only DMARD in patients with early, severely active RA who lack poor prognostic factors [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14,25\">",
"       14,25",
"      </a>",
"      ]. This approach is consistent with the recommendations of the American College of Rheumatology [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Discontinuation of SSZ due to toxicities may be required after two and five years of treatment in up to 30 and 50 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/23\">",
"       23",
"      </a>",
"      ]. Other studies suggest rates that are similar to those of LEF and MTX [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/52\">",
"       52",
"      </a>",
"      ]. The most common toxicities include gastrointestinal upset, headache, and rash [",
"      <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/55\">",
"       55",
"      </a>",
"      ]. Data that support the use of sulfasalazine in moderately to severely active RA are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"       \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H344394776#H344394776\">",
"       \"General principles of management of rheumatoid arthritis in adults\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other &ndash; Additional nonbiologic alternatives to MTX are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"       \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adverse effects of LEF and SSZ are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link&amp;anchor=H5#H5\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link&amp;anchor=H4#H4\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link&amp;anchor=H12#H12\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\", section on 'Measures to minimize side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3694939\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoids act rapidly to control inflammation but do not provide adequate benefit for longer-term control of disease or for prevention of joint injury in most patients. Moreover, chronic use of these agents, particularly glucocorticoids in moderate to high doses, is associated with significant risk of adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of selective COX-2 inhibitors\", section on 'Toxicities and possible toxicities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We, thus, use these medications primarily for temporary control of disease activity in patients in whom treatment is being started with disease-modifying antirheumatic drugs (DMARDs) or in whom adjunctive treatment is needed for persistent or flaring disease until treatment with DMARDs is sufficiently effective. Some patients require ongoing use of such agents despite other therapies, but neither NSAIDs nor glucocorticoids should be considered as substitutes for effective treatment with DMARDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We use NSAIDs initially in most patients with moderately to severely active disease. We also initiate therapy with glucocorticoids in patients on the more severe end of this spectrum, while patients with less active disease who do not respond adequately to NSAIDs within two weeks should also receive treatment with glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3693478\">",
"    <span class=\"h2\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs should be used at full therapeutic antiinflammatory doses for initial therapy of patients with moderately to severely active RA, unless contraindicated by gastrointestinal or renal disease or by heart failure. NSAIDs also provide analgesic benefit.",
"   </p>",
"   <p>",
"    The dose of NSAIDs is titrated to the optimum tolerated level and is continued for at least two weeks before switching agents, because maximal analgesic and antiinflammatory effect is usually achieved within 10 to 14 days. The dose and duration of NSAIDs previously tried by the patient should be identified to determine if an adequate trial of one or more NSAIDs has already been attempted. The dose of a given medication required by different patients may vary. Examples of effective antiinflammatory doses include 3200 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , 1000 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , or a single daily dose of a longer acting agent such as 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    . A reduced dose and more frequent monitoring may be needed in older patients and in others who may be at greater risk of adverse effects, including renal insufficiency due to comorbidities or other medication use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients at increased risk of NSAID gastropathy, such as those who are also receiving glucocorticoids or who have a history of peptic ulcer disease, appropriate measures should be undertaken to decrease risk of gastrointestinal complications such as use of a proton pump inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , or possibly use of a selective COX-2 inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) rather than a nonselective NSAID. Alternatives to the non-salicylate NSAIDs in such patients also include the non-acetylated salicylates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    at 2000 to 3000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which have proven antiinflammatory activity with fewer adverse gastrointestinal effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H5#H5\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Celecoxib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be cautioned regarding the risks of chronic use of NSAIDs. Effective management with DMARDs should allow for the discontinuation of daily full-dose NSAID use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic trials of individual NSAIDs can continue until the patient has achieved adequate control of the inflammation with minimal side effects. Clinical experience indicates that there are relatively little or no benefit and an increased risk of gastrointestinal toxicity when adding one NSAID to another. Treatment with glucocorticoids should be offered if adequate symptomatic relief is not achieved within 10 to 14 days on NSAIDs alone, while awaiting benefit from DMARD therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3693989\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids act to rapidly reduce symptoms due to inflammatory synovitis in patients with RA. Oral glucocorticoids are commonly used in RA, and some patients may benefit from intraarticular or intramuscular glucocorticoid administration in this setting. Glucocorticoid use is discussed briefly below. A more detailed discussion of glucocorticoid use in RA and of the data supporting its efficacy is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1488242\">",
"     'Therapy for resistant disease and flares'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3985847\">",
"     'Intraarticular glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1487863\">",
"     'Intramuscular glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3695299\">",
"     'Oral glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is also evidence that glucocorticoids retard radiographic progression in patients with RA in the short to medium term [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. However, these agents should not be used alone for an extended period, and long-term treatment with glucocorticoids should be avoided, since their use may be associated with increased morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\", section on 'Efficacy of chronic use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3695299\">",
"    <span class=\"h3\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the use of oral glucocorticoids to help control disease activity in the initial treatment of severely active RA, particularly in early disease, and in the treatment of patients with less severe disease in whom a trial of NSAIDs has been inadequate. We use glucocorticoids in addition to NSAIDs because of their extremely rapid onset of action and the greater effectiveness in controlling symptoms for most patients with active RA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/60\">",
"     60",
"    </a>",
"    ]. Based upon our clinical experience, we usually initiate therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    5 to 20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    depending upon the severity of joint inflammation and upon the minimal dose required to obtain initial control. Most patients can be adequately controlled on 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    while initiating DMARDs.",
"   </p>",
"   <p>",
"    Glucocorticoids should then be tapered as rapidly as tolerated with the goal of further tapering and eventual discontinuation, if possible, once disease control is achieved and can be maintained. In general, the beneficial effects of DMARD therapy will permit reduction and discontinuation of the glucocorticoids, a goal of successful DMARD therapy, within four to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of glucocorticoids in this setting has been shown in randomized trials and in a large number of observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/60\">",
"     60",
"    </a>",
"    ]. Some studies have used relatively high-dose glucocorticoids for initial therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or equivalent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/3,61\">",
"     3,61",
"    </a>",
"    ]. However, lower doses are usually adequate when combined with effective DMARDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are numerous risks associated with glucocorticoid use, and appropriate monitoring and precautions should be performed in all patients on these medications with respect to risks for osteoporosis, diabetes, and other adverse effects of hypercortisolism. RA is considered an independent risk factor for osteoporotic fracture, and a fracture risk assessment should be performed to help guide treatment decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H2#H2\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Assessment of fracture risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1487863\">",
"    <span class=\"h3\">",
"     Intramuscular glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who must avoid daily oral glucocorticoids or who require an extremely rapid antiinflammatory response, an alternative to oral glucocorticoids is a single initial intramuscular injection of a depot preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (80 to 120 mg), administered by deep intramuscular injection into the gluteal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Based upon the overall clinical response, up to two subsequent injections may be required at intervals of every four weeks to maintain improvement in symptoms, signs, and physical function, while slower-acting DMARDs exert their expected effect on controlling disease activity. Longer-term use is avoided to prevent harmful effects of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3985847\">",
"    <span class=\"h3\">",
"     Intraarticular glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular injections of long-acting glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide) are used to reduce synovitis in particular joints that are more inflamed than others. In such patients, it may be difficult to distinguish between active joint inflammation due to RA alone and that due to infection. Thus, when clinically indicated, joint fluid should be obtained to exclude infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link&amp;anchor=H14#H14\">",
"     \"Septic arthritis in adults\", section on 'Rheumatoid arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2986439\">",
"    <span class=\"h1\">",
"     ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the medications noted above, we use analgesic medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , for additional pain relief if required. We avoid the use of opioids because pain can be controlled in most patients with RA by effective use of NSAIDs, glucocorticoids, and DMARDs that control the disease process. Patients without evidence of very significant joint injury who appear to require opioids for adequate pain relief despite good control of disease activity should be evaluated for other comorbid conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MONITORING AND REEVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease activity and the response to therapy should be regularly reassessed, along with monitoring for drug toxicities, every three to five weeks until the patient is stable and disease is under control [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/9,56,65,66\">",
"     9,56,65,66",
"    </a>",
"    ]. Subsequently, frequency of assessments should generally be no fewer than every three months. Well-controlled patients who are seen less frequently may require laboratory monitoring beyond that performed at scheduled visits and should be counseled, as should all patients, to contact their treating clinician if the arthritis flares. Laboratory testing for the monitoring of disease activity and for the monitoring and prevention of drug toxicity is discussed separately.",
"   </p>",
"   <p>",
"    We periodically reevaluate disease activity using a quantitative composite measure at each assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H6422708#H6422708\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Tight control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H344392649#H344392649\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Assessment of disease activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More frequent laboratory monitoring may be required depending on the medications being used and following increases in dosing; more frequent clinical assessments may be required in patients experiencing a flare of disease or undergoing changes in therapy. We alter therapy if the disease remains active or progresses. (See",
"    <a class=\"local\" href=\"#H3986034\">",
"     'Disease resistant to initial DMARD therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1488242\">",
"    <span class=\"h1\">",
"     THERAPY FOR RESISTANT DISEASE AND FLARES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3985983\">",
"    <span class=\"h2\">",
"     Disease resistant to initial symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We take the following approaches in patients who exhibit a persistent inflammatory synovitis that is resistant to the initial symptomatic therapies described above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We add oral glucocorticoids in patients begun on NSAIDs and DMARDs who continue to experience significant symptoms after 10 to 14 days of therapy. (See",
"      <a class=\"local\" href=\"#H3695299\">",
"       'Oral glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use intraarticular glucocorticoids in individual joints when only a small number are resistant to therapy with systemic agents or if it is anticipated that a local injection may preclude the need for NSAIDs or systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H3985847\">",
"       'Intraarticular glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3986034\">",
"    <span class=\"h2\">",
"     Disease resistant to initial DMARD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients who fail to achieve remission or low disease activity within three to six months of initiating therapy or who require more than approximately 5 to 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent glucocorticoid chronically to maintain a state of remission or low disease activity receive a more potent DMARD or combination of DMARDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3986086\">",
"    <span class=\"h2\">",
"     Flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA has natural exacerbations (also known as flares) and reductions of continuing disease activity. It is important to distinguish a disease flare, characterized by symptoms and physical and laboratory findings of increased inflammatory synovitis, from noninflammatory causes of local or generalized increased pain. The severity of the flare and background drug therapy influence the choice of therapies. Drug therapy for flares is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3697757\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with moderately to severely active RA will require sustained therapy and adjustments in their treatment regimen over months to years to achieve treatment goals. In the minority of patients who achieve a sustained clinical remission of greater than one year, we cautiously try to reduce DMARD doses while maintaining close monitoring to facilitate recognition of any recurrence of disease activity. Although some patients may tolerate a reduced dose of medications, whether or not to discontinue DMARDs in patients in remission remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/15,67\">",
"     15,67",
"    </a>",
"    ]. We prefer to continue nonbiologic or biologic DMARD therapy at reduced doses, if possible, but do not discontinue DMARD therapy in most patients who have had moderately to severely active RA. Cautious reduction of biologic DMARD doses can be performed by increasing the interval between doses or by reducing the medication dose [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H6422708#H6422708\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Tight control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link&amp;anchor=H344392649#H344392649\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Assessment of disease activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, in a patient in clinical remission being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (7.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and MTX (20",
"    <span class=\"nowrap\">",
"     mg/week),",
"    </span>",
"    we would first try to reduce prednisone because of the risk of long-term adverse effects with glucocorticoids. In such a patient, we would lower the glucocorticoid dose slowly (no faster than an average of 1 mg every two to four weeks), as long as there was no recurrence of disease activity. If prednisone can be discontinued, or cannot but can be lowered to a dose no greater than 5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    we next decrease MTX. We reduce the MTX dose in 2.5 mg increments every two to three months as tolerated but generally to no lower than 15",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    A lower dose of MTX (eg, 10 to 12.5",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    may be adequate to maintain remission in patients who are older or who have diminished renal function.",
"   </p>",
"   <p>",
"    Continued close monitoring is required in patients who discontinue their medications and who enter a period of possible drug-free remission. The risk of disease recurrence in such patients is high, and flares of disease may occur even several years after stopping therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/67-72\">",
"     67-72",
"    </a>",
"    ]. Additionally, clinical remission can be difficult to achieve upon resumption of DMARD therapy in patients who have discontinued all DMARDs. The best candidates for achieving a drug-free remission appear to be patients with the following characteristics: a short duration of symptoms when treatment is started, male sex, the absence of autoantibodies, and receipt of early intensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/3/31802/abstract/61,70,72,73\">",
"     61,70,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"       \"Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with moderately to severely active rheumatoid arthritis (RA) typically meet the",
"      <span class=\"nowrap\">",
"       ACR/EULAR",
"      </span>",
"      criteria for RA, have at least five inflamed joints and elevated acute phase reactants, usually have positive tests for rheumatoid factor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anticyclic citrullinated peptide antibodies, and sometimes exhibit early radiographic changes consistent with inflammatory arthritis and joint injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of moderately to severely active RA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients with moderately to severely active RA, we recommend treatment with a disease modifying antirheumatic drugs (DMARD), rather than use of antiinflammatory agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glucocorticoids alone and delay of DMARD therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Additional principles for the treatment of RA include achievement and maintenance of tight control of disease activity, with the ideal goal of remission; use of antiinflammatory agents, including glucocorticoids, only as adjunctive agents; and participation of a rheumatologist in the evaluation and ongoing care of the patient. (See",
"      <a class=\"local\" href=\"#H3692872\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient education and other nonpharmacologic and preventive therapies are needed for all patients with RA. (See",
"      <a class=\"local\" href=\"#H2985885\">",
"       'Nonpharmacologic and preventive therapies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link\">",
"       \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) be used as the initial DMARD for patients with moderately to severely active RA, rather than another single nonbiologic or biologic DMARD or combination therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Doses are increased as tolerated and as needed, up to 25",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      to control symptoms and signs of arthritis. Subcutaneous administration may be of benefit in patients with an inadequate response to orally administered MTX at a dose of 25",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      of MTX. (See",
"      <a class=\"local\" href=\"#H3981583\">",
"       'Initial therapy with methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative DMARDs for patients unable to take MTX include a tumor necrosis factor inhibitor, preferably",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      . We limit the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      as an alternative to MTX to patients who do not have any poor prognostic features, who have a strong preference for an oral agent, and in whom leflunomide is contraindicated. (See",
"      <a class=\"local\" href=\"#H3982784\">",
"       'Alternatives to MTX'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3982842\">",
"       'TNF inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3982900\">",
"       'Nonbiologic DMARD alternatives to MTX'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with moderately to severely active RA, we use antiinflammatory drug therapy with nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoids, preferably on a temporary basis, to quickly achieve control of signs and symptoms of disease. We use nonsteroidal antiinflammatory drugs (NSAIDs) in all patients without contraindications to their use. In patients with more severe disease or with moderate disease resistant to a brief course of NSAIDs, we suggest the use of glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We then taper and withdraw these medications once DMARDs have taken effect. We use intraarticular injections of long-acting glucocorticoids to reduce synovitis in particular joints that are more inflamed than others. When clinically indicated, joint fluid should be obtained to exclude infection. (See",
"      <a class=\"local\" href=\"#H3693478\">",
"       'NSAIDs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3693989\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the initial treatment of patients with moderately to severely active RA, the patient should be reevaluated every three to five weeks for the effectiveness of therapy and for the monitoring of possible drug toxicity. We advise the periodic reevaluation of disease activity using a quantitative composite measure at each assessment. In patients who fail to achieve remission within three to six months of initiating therapy or who require more than approximately 5 to 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent glucocorticoid on a chronic basis to maintain a state of remission or low disease activity, we suggest using a more potent DMARD or combination of DMARDs rather than continuing the same treatment regimen for a longer period of time (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Monitoring and reevaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3692872\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/1\">",
"      Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/2\">",
"      Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/3\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/4\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/5\">",
"      de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/6\">",
"      M&ouml;tt&ouml;nen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/7\">",
"      Puolakka K, Kautiainen H, M&ouml;tt&ouml;nen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/8\">",
"      Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/9\">",
"      Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/10\">",
"      Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/11\">",
"      Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/12\">",
"      Sokka T, Kautiainen H, H&auml;kkinen A, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004; 31:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/13\">",
"      Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/14\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/15\">",
"      Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/16\">",
"      Huizinga TW, Pincus T. In the clinic. Rheumatoid arthritis. Ann Intern Med 2010; 153:ITC1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/17\">",
"      Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/18\">",
"      Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 2006; 55:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/19\">",
"      Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/20\">",
"      Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:906.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Rheumatoid arthritis: The management of rheumatoid arthritis in adults file://guidance.nice.org.uk/CG79 (Accessed on March 29, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/22\">",
"      Suarez-Almazor ME, Belseck E, Shea B, et al. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; :CD000957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/23\">",
"      Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/24\">",
"      Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 2005; 44:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/25\">",
"      Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/26\">",
"      Choy EH, Smith C, Dor&eacute; CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005; 44:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/27\">",
"      Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/28\">",
"      Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/29\">",
"      Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/30\">",
"      Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/31\">",
"      Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008; 58:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/32\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/33\">",
"      Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998; 25:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/34\">",
"      van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/35\">",
"      Moreland LW, O'Dell JR, Paulus H, et al. TEAR: Treatment of early aggressive RA: A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum 2009; 60:S707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/36\">",
"      Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/37\">",
"      Choi HK, Hern&aacute;n MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/38\">",
"      Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/39\">",
"      Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2010; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/40\">",
"      Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010; 62:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/41\">",
"      St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/42\">",
"      Moreland LW, O'Dell JR, Paulus HE, et, al. Two-year radiographic results from the TEAR trial. Arthritis Rheum 2010; 62:S568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/43\">",
"      McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/44\">",
"      Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/45\">",
"      Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; :CD008794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/46\">",
"      Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/47\">",
"      Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/48\">",
"      Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/49\">",
"      Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/50\">",
"      Kalden JR, Scott DL, Smolen JS, et al. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol 2001; 28:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/51\">",
"      Larsen A, Kvien TK, Schattenkirchner M, et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001; 30:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/52\">",
"      Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; :CD002047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/53\">",
"      Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/54\">",
"      Hewitson PJ, Debroe S, McBride A, Milne R. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J Clin Pharm Ther 2000; 25:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/55\">",
"      Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997; 36:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/56\">",
"      Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Med Clin North Am 1997; 81:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/57\">",
"      Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/58\">",
"      Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; :CD006356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/59\">",
"      Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009; 68:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/60\">",
"      G&oslash;tzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/61\">",
"      van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/62\">",
"      Choy EH, Kingsley GH, Corkill MM, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol 1993; 32:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/63\">",
"      Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005; 64:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/64\">",
"      Verstappen SM, McCoy MJ, Roberts C, et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 2010; 69:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/65\">",
"      Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/66\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/67\">",
"      O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010; 69:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/68\">",
"      ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/69\">",
"      Tiippana-Kinnunen T, Paimela L, Kautiainen H, et al. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol 2010; 39:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/70\">",
"      Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol 2010; 6:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/71\">",
"      Berthelot JM, Varin S. Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents? Joint Bone Spine 2004; 71:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/72\">",
"      Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/3/31802/abstract/73\">",
"      Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011; 13 Suppl 1:S3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7491 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31802=[""].join("\n");
var outline_f31_3_31802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3692501\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF MODERATELY TO SEVERELY ACTIVE RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3692872\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2985885\">",
"      NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      APPROACH TO DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3981569\">",
"      DMARD THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3981576\">",
"      Pretreatment interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3981583\">",
"      Initial therapy with methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982770\">",
"      - MTX dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3984111\">",
"      - Side effects, monitoring, and other considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H207103444\">",
"      - MTX versus other DMARDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H207103451\">",
"      - MTX versus initial combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982784\">",
"      Alternatives to MTX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982842\">",
"      - TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3982900\">",
"      - Nonbiologic DMARD alternatives to MTX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3694939\">",
"      SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3693478\">",
"      NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3693989\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3695299\">",
"      - Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1487863\">",
"      - Intramuscular glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3985847\">",
"      - Intraarticular glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2986439\">",
"      ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MONITORING AND REEVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1488242\">",
"      THERAPY FOR RESISTANT DISEASE AND FLARES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3985983\">",
"      Disease resistant to initial symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3986034\">",
"      Disease resistant to initial DMARD therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3986086\">",
"      Flares",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3697757\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/457?source=related_link\">",
"      Effects of antiinflammatory and immunosuppressive drugs on gonadal function in men with rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=related_link\">",
"      Initial treatment of mildly active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=related_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=related_link\">",
"      Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=related_link\">",
"      Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_3_31803="Pediatric thoracic injuries";
var content_f31_3_31803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric thoracic injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immediately life-threatening (usually suspected on initial assessment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flail chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tension pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massive hemothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Potentially life-threatening (usually noted on secondary survey, chest radiograph, ECG, or reevaluation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheobronchial tear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary contusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial contusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruptured diaphragm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic transection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Generally not life-threatening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simple pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small hemothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rib fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest wall laceration/contusion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31803=[""].join("\n");
var outline_f31_3_31803=null;
var title_f31_3_31804="5-FU treatment VAIN";
var content_f31_3_31804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    5-FU treatment of vaginal intraepithelial neoplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients treated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurred after first treatment, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment schedule",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow- up range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Woodruff",
"       </td>",
"       <td>",
"        1975",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        BID x 1 month then monthly",
"       </td>",
"       <td>",
"        6 wks-6 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piver",
"       </td>",
"       <td>",
"        1979",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        QD x 5 days/mo for 2-3 mo",
"       </td>",
"       <td>",
"        3-7 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ballon",
"       </td>",
"       <td>",
"        1979",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        BID x 2 wks",
"       </td>",
"       <td>",
"        6-30 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daly",
"       </td>",
"       <td>",
"        1980",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        BID x 10-14 d",
"       </td>",
"       <td>",
"        2-5 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Petrilli",
"       </td>",
"       <td>",
"        1980",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        BID x 5 d",
"       </td>",
"       <td>",
"        2-60 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caglar",
"       </td>",
"       <td>",
"        1981",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        QD x 5-10 d",
"       </td>",
"       <td>",
"        3-48 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kirwan",
"       </td>",
"       <td>",
"        1985",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        Qweek x 10 wks",
"       </td>",
"       <td>",
"        4-42 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Krebs",
"       </td>",
"       <td>",
"        1989",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        Qweek x 10 wks",
"       </td>",
"       <td>",
"        12-84 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Audet-LaPointe",
"       </td>",
"       <td>",
"        1990",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        QD x 5 d",
"       </td>",
"       <td>",
"        9-42 mo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dodge",
"       </td>",
"       <td>",
"        2001",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        not stated",
"       </td>",
"       <td>",
"        &gt;7mo",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31804=[""].join("\n");
var outline_f31_3_31804=null;
var title_f31_3_31805="Survival with HBV cirrhosis";
var content_f31_3_31805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Survival in patients with cirrhosis from hepatitis B virus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-term survival in 98 patients with HBV-related cirrhosis with and without decompensated disease at study entry. Survival was markedly better in those with compensated cirrhosis (84 versus 14 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from DeJongh FE, Janssen JL, DeMan RA, et al, Gastroenterology 1992; 103:1630.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31805=[""].join("\n");
var outline_f31_3_31805=null;
var title_f31_3_31806="Congenital toxoplasmosis intracranial calcifications";
var content_f31_3_31806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital toxoplasmosis intracranial calcifications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 207px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Brain computed tomographic scan showing small, calcified lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lynfield R, Guerina G. Toxoplasmosis. Pediatr Rev 1997; 18:75. Copyright &copy; 1997 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31806=[""].join("\n");
var outline_f31_3_31806=null;
var title_f31_3_31807="Ichthyosiform sarcoidosis";
var content_f31_3_31807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ichthyosiform sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ichthyosiform sarcoidosis. Infiltrated plaques with hyperpigmented polygonal scales, involving the foot and anterior leg are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_3_31807=[""].join("\n");
var outline_f31_3_31807=null;
